Immunocontraception vaccines and methods for production
Recombinant poxvirus vectors, like SWPV, provide a single-dose solution for ASFV protection and immunocontraception, overcoming current vaccine limitations by inducing robust immune responses and humane population control in domestic and wild swine.
Patent Information
- Application Number
- PCT/US2026/027584
- Authority / Receiving Office
- WO · WO
- Patent Type
- Applications
- Current Assignee / Owner
- Priority Date
- 2026-03-06
- Filing Date
- 2026-05-11
- Publication Date
- 2026-11-12
AI Technical Summary
Current ASFV vaccines face challenges in providing robust protection against virulent strains, safety concerns, and logistical issues, while immunocontraceptive vaccines require multiple doses and are species-specific, making them impractical for large-scale application in feral or wild animal populations.
Recombinant poxvirus vectors, such as attenuated Swinepox Virus (SWPV), engineered to express ASFV antigens or immunocontraceptive polypeptides, offering a single-dose, species-specific solution for disease prevention and population control, with potential for self-dissemination.
The recombinant poxvirus vectors induce robust immune responses and long-lasting immunocontraception, effectively controlling ASFV and managing animal populations with scalability and safety, addressing both infectious disease and overpopulation challenges.
Smart Images

Figure IMGF000050_0001_TABLE 
Figure IMGF000050_0002_TABLE 
Figure IMGF000051_0001_TABLE
Abstract
Description
[0001] Docket No. 501.102. PCT
[0002] IMMUNOCONTRACEPTION VACCINES AND METHODS FOR PRODUCTION
[0003] CROSS-REFERENCE INFORMATION
[0004] This present application is an international patent application that claims priority to US Provisional Serial No.63 / 803,240 filed on May 9, 2025 and US Provisional Serial No.63 / 998,682 filed on March 6, 2026, which are each incoiporaled by reference herein in its entirety.
[0005] SEQUENCE LISTINGS
[0006] The present application is being filed along with a Sequence Listing in electronic foimat The Sequence Listing is provided as a file entitled TF01 PCT_SEQLIST.xml, created on May 10, 2026, which is 105.00 kilobytes in size. The information in the electronic foimat of the Sequence Listing is incoiporaled by reference in its entirely.
[0007] BACKGROUND
[0008] African Swine Fever Virus (ASFV) represents a significant and persistent threat to global swine health and the agricultural economy. ASFV is a highly contagious hemoirhagic disease affecting domestic pigs and wild boar, often characterized by extremely high mortality rates, approaching 100% in susceptible herds. The lack of a widely available licensed commercial vaccine means that outbreaks typically result in drastic measures, including mass culling of animals, severe international trade restrictions, and substantial economic losses amounting to billions of dollars annually. Controlling the spread of ASFV is exceptionally challenging due to its environmental stability and transmission through various routes, including direct contact, contaminated fomites, and biological vectors like ticks.
[0009] Current efforts to develop effective ASFV vaccines have encountered significant hurdles. Conventional approaches, such as inactivated or subunit vaccines, primarily induce antibody responses but generally fail to provide robust protection against challenge with virulent ASFV strains. Live-attenuated virus (LAV) vaccines or gene-deleted vaccine candidates have shown more promise in experimental settings, potentially inducing both humoral and cellular immunity. However, these approaches carry inherent safety concerns, including the risk of residual virulence causing severe post-vaccination reactions, potential reversion to virulence, chronic canier states, and shedding of vaccine virus, making them problematic for widespread field use, especially in regions free of ASFV. While newer strategies employing viral vectors like adenovirus or vesicular stomatitis virus to deliver ASFV antigens have demonstrated potential in eliciting protective immunity in some studies, challenges remain in developing a vaccine that is safe, effective across diverse ASFV genotypes, provides long-lasting immunity ideally after a single dose, and is suitable for deployment in varied pig populations, including wild or feral swine. The establishment and persistence of ASFV in feral swineDocket No. 501.102. PCT
[0010] populations represents a critical challenge for disease control and eradication efforts, acting as a reservoir for potential spillover into domestic pig populations and complicating prevention strategies.
[0011] Concuirent with the challenges posed by infectious diseases like ASFV, the management of wild and feral animal populations presents significant ecological, agricultural, and animal welfare concerns. Species such as wild boar, feral dogs, feral cats, and others can cause extensive environmental damage, negatively impact native wildlife, contribute to agricultural losses, and pose public health risks. Traditional methods for controlling these populations, such as culling, trapping, poisoning, or aerial shooting, are frequently employed but are often criticized for being inhumane, costly, logistically complex, and ultimately ineffective in achieving sustainable long-term population reduction. Public opposition to lethal control methods is also increasing.
[0012] More humane alternatives focus on fertility control. Surgical sterilization (spaying and neutering) is the standard for companion animals and is highly effective, but it is invasive, requires anesthesia, veterinary expertise, postoperative care, and individual animal capture and handling, making it impractical and cost-prohibitive for large-scale application in fiee-roaming feral or wild animal populations. Chemical castration methods have also been explored but may be limited in applicability (e.g., males only) or availability.
[0013] Immunocontraception, which uses the animal's own immune system to induce infertility (e.g., by targeting reproductive hormones like Gonadotropin-Releasing Hormone (GnRH) or zona pelludda proteins), offers a promising non-surgical approach. Existing immunocontraceptive vaccines, such as GonaCon™ or Porcine Zana Pellucida (PZP) vaccines, have shown efficacy in certain species like deer, wild horses, and some feral populations. However, these often suffer from limitations including the need for multiple doses (initial vaccination plus boosters) to achieve and maintain efficacy, variable duration of effect across species and individuals, and logistical challenges associated with repeated capture or treatment of target animals Furthermore, the development of immunocontraceptive agents that are species-specific, effective after a single administration, long-lasting, safe, and potentially deliverable through mechanisms suitable for wildlife management (e.g, remote delivery or potential transmissibility within the target species) remains an area of active research.
[0014] Therefore, there exists a pressing need for innovative, safe, and effective platform technologies capable of addressing both critical infectious diseases in livestock and wildlife, such as ASFV, and the challenges of humane animal population management - for both wild and companion animals. Specifically, there is a need for vaccine vectors and compositions that can deliver immunocontraceptive agents effectively, ideally via a single-dose, species-specific, and scalable approach, potentially overcoming the limitations of current population management strategies.Docket No. 501.102. PCT
[0015] SUMMARY OF INVENTION
[0016] The present disclosure relates generally to the fields of virology, genetic engineering, and immunology. More specifically, the disclosure relates to recombinant poxvirus vectors, compositions comprising such vectors, and methods for their use in modulating immune responses in animal populations. Applications include, but are not limited to, species-specific vaccines for preventing infectious diseases, such as African Swine Fever Virus (ASFV) in swine, and for inducing immunocontraception, potentially through transmissible vaccine platforms.
[0017] The present disclosure addresses the aforementioned needs by providing an invention that is a platform biotechnology encompassing: (i) recombinant poxvirus vectors; (ii) compositions comprising said vectors; and (iii) methods of use of in said vectors for (a) inducing immunocontraception in target animal populations, and / or (b) eliciting protective immunity against infectious diseases. The invention herein leverages the unique properties of recombinant poxviruses, particularly large genome capacity of the recombinant poxviruses for expressing multiple heterologous genes; and potential of recombinant poxviruses for species-specific adaptation, to create versatile and effective biobgical tools.
[0018] In one aspect of the platform biotechnology, recombinant poxviruses, such as attenuated Swinepox Virus (SWPV), can be engineered to express one or more antigens from pathogenic organisms. For example, recombinant SWPV vectors are described that express a plurality of African Swine Fever Virus (ASFV) antigens. These antigens can be selected from those known to elicit protective immune responses, including, but not limited to, CP204L, E183L, EP402R, B646L, B602L, E199L, EP153R, F317L, and MGF505-5R. The recombinant poxviruses are designed to be safe, capable of replication in target cells or animals to an extent sufficient to express the heterologous antigens and induce a robust immune response, and are preferably effective after a single administration. These vaccine candidates are particularly suited for controlling diseases like ASFV in both domestic and wild swine populations, thereby addressing a significant threat to animal health and agriculture.
[0019] In another aspect of the platform biotechnology, the recombinant poxviruses can be engineered to express polypeptides capable of inducing immunocontraception in a target animal species. Such polypeptides may include reproductive hormones (e.g, Gonadotropin-Releasing Hormone, GnRH), proteins involved in gamete function or fertilization (e.g, zona pelludda proteins), or other immunomodulatory molecules that disrupt reproductive processes when targeted by the host immune system. The species-specificity of the chosen poxvirus vector (e.g, SWPV for swine, or other species-specific poxviruses for other target animals like canids, felids, rodents, etc.) ensures targeted delivery and effect These immunocontraceptive vectors can provide a humane, non-surgical, single-dose, and long-lasting method for animal population control.
[0020] A significant advantage of the platform technology disclosed herein is the potential for d ual-p urpose applications. For example, a single recombinant poxvirus vector can be engineered to express both antigens for disease prevention (e.g, ASFV antigens) andDocket No. 501.102. PCT
[0021] polypeptides for immunocontraception, thereby simultaneously addressing disease risk and overpopulation in a target species like wild boar.
[0022] Furtheimoie, certain embodiments of the immunocontracepfive vectors are envisioned to possess characteristics of transmissibility, wherein the vaccine can spread from a vaccinated animal to unvaccinated conspe fics within a population through natural animal-to-animal contact This "ncxfose" or self-disseminating approach offers a highly scalable and cost-effective means of achieving widespread immunocontraception in feral or wild animal populations where individual capture and treatment are impractical.
[0023] The platform biotechnology further comprises nucleic acid constructs suitable for generating the recombinant poxviruses described herein. Such constructs are designed, for example, as plasmids containing appropriate poxvirus genomic sequences flanking one or more expression cassettes encoding the heterologous polypeptide®, configured to facilitate homologous recombination upon introduction into a suitable host cell or system. Furthermore, the platform herein encompasses methods for generating, purifying, and characterizing these recombinant poxviruses, induding techniques for assessing antigen expression, attenuation, replication kinetics, and genetic stability, using approaches known in the art or adapted therefrom.
[0024] Compositions, such as vaccines, comprising the recombinant poxviruses and a pharmaceutically or veterinarily acceptable carrier are provided. These compositions are suitable for administration to target animals via various routes, including parenteral, oral, or mucosal routes.
[0025] Methods of indudng an immune response against a pathogen (e.g, ASFV) in an animal, and methods of indudng immunocontracepfion in an animal, comprising administering an effective amount of the recombinant poxvirus or composition thereof, are also within the scope of the invention. The methods are applicable to a range of animal species, with the poxvirus vector being selected for its tropism and safety in the target spedes.
[0026] The inventions described herein offer a novel and advantageous platform for developing spedes-specific biological interventions for both disease control and humane population management, addressing critical unmet needs in veterinary medidne, agriculture, and wildlife conservation.
[0027] BRIEF DESCRIPTION OF THE DRAWINGS
[0028] The patent or application file contains at least one drawing executed in color. Copies of this patent or patent application publication with color drawing® will be provided by the Office upon request and payment ofthe necessary fee.Docket No. 501.102. PCT
[0029] FIG. 1 A is a schematic diagram illustrating the principle of animal-to-animal transmission of a recombinant poxvirus vector, such as an immunocontraceptive vaccine, within a target animal population, initiated by the treatment of one or more individuals.
[0030] FIG. 1 B is a dual-panel illustration depicting the reproductive hoimone cascade and the five-step mechanism of the immunoconlraceptive vaccine platform. The left panel shows a labeled anatomical diagram of a target pest animal (rodent or wild boar) highlighting the hypothalamus, gonadotropins, testes, ovary, and germ cells of the gonads.
[0031] FIG. 1 C is a schematic depiction of the vaccine design and mechanism of action. The figure shows the integration of three components: GnRH peptide (shown as small red circles), an immunogenic protein carrier (shown as a blue structure), and a linkage between them (shown as a connecting line), which together form an immunogenic protein-GnRH fusion. The figure further depicts the c fused antigen being encoded by DNA (shown as a double helix) and encapsulated within a viral vector (shown as a spherical particle). The complete vaccine construct is then administered to an animal via vaccination (shown by an arrow pointing to a vaccinated animal). Upon vaccination, the viral vector delivers the genetic material to animal cells, resulting in production of the immunogenic protein-GnRH fusion within the cell, which triggers an immune response (shown by antibodies and immune activation).
[0032] FIG.2A is a schematic diagram illustrating an exemplary mechanism of action for a recombinant viral vector-based immunocontraceptive vaccine, depicting: the engineering of a viral vectorto carry genetic material encoding a reproductive hormone or related antigen, administration of the vector, expression of the antigen within a host cell, subsequent generation of antibodies by the host immune system against the antigen, and the neutralization of the endogenous reproductive hormone by these antibodies, leading to infertility. The steps are numbered 110 through 710, each depicting a distinct phase of the immunization process. In step 110, a gene encoding a canine reproductive hormone (GnRH) is being combined with DNA from bacteria (the immunogenic protein carrier), represented by labeled DNA segments. In step 210, the combined DNA being is inserted into a weakened virus used as a vaccine vehicle, shown by the combined DNA entering a virus particle. In step 310, the vaccine is being injected or delivered orally (depicted by a syringe and an animal receiving the vaccine). In step 410, cellular uptake of the vaccine occurs within 3 to 10 days, with the vaccine particle entering a cell and delivering the genetic material. In step 510, the protein antigen (the GnRH-immunogenic protein fusion) is produced within the infected cell, with the antigen being produced intracellularly and presented on the cell surface (shown by antigen molecules on the cell membrane). In step 610, the immune system recognizes the antigen as foreign, with antibodies (depicted as Y-shaped structures) being produced against the antigen. In step 710, the antibodies generated against the antigen are additionally neutralizing the native reproductive hormones, binding to and blocking their interaction with cellular receptors, leading to contraception and long-term sterilization. The antigen resembles the native reproductive hormones produced by the animal, thereby the antibodies can be generated that neutralize the native reproduction hormones produced by the animal.Docket No. 501.102. PCT
[0033] FIG.2B is a seven-step schematic illustration depicting an alternative gene therapy mechanism of action. The steps are numbered 11 through 17 of the gene therapy process /
[0034] FIG.3 is fluorescence microscopy images demonstrating the successful infection of various porcine cell lines (Testis, Immune Cells, Kidney Cells, Nasal cells) by a recombinant Swinepox Virus (SWPV) vector engineered to express Green Fluorescent Protein (GFP). The green fluorescence indicated transgene expression and confirmed the vector's ability to infect and function in these cell types.
[0035] FIG.4 is Western blot analyses demonstrating the expression of exemplary immunocontraceptive fusion proteins in cells infected with recombinant SWPV vaccine candidates. Specific antibodies were used to detect Gonadotropin-Releasing Hormone (GnRH) fusion proteins (e.g., STF2-GnRH and MBP-GnRH) expressed by different vaccine constructs (Vaccine Candidate 1," 'Vaccine Candidate 4"), which confirmed successful transgene protein production. Control lanes included mock-infected cells and cells infected with wild-type virus or a viral vector control. Actin served as a loading control.
[0036] FIG.5 is a bar graph summarizing preliminary results from an in vivo study in pigs (n=6, labeled 1 -6), wherein: Optical Density (OD) measurements at 450 nm from an ELISA detecting anti-GnRH antibodies in serum samples were collected before vaccination Day 0, red bars) and 30 days post-vaccination (Day 30, green bars) with a recombinant SWPV-GnRH candidate vaccine. An increase in OD from Day 0 to Day 30 indicated the induction of an anti-GnRH antibody response.
[0037] FIG.6 is a schematic representation of the expression cassettes within two exemplary recombinant SWPV immunocontraceptive vaccine constructs, designated TF10 and TF11. The diagrams illustrate genetic elements and arrangement of the antigenencoding sequences within the poxvirus vector, such as a promoter (e.g., mH5), an optional signal peptide (e.g., CD33 sp), and the coding sequences for the GnRH fusion proteins (STF2-GnRH and MBP-GnRH).
[0038] FIG.7 is a line graph showing the body weight (in kilograms) of individual pigs overtime (days post vaccination) from the in wvo study utilizing the constructs described in FIG.6 and further detailed in subsequent figures. Animals were grouped as Mock-vaccinated (animals 1, 2), vaccinated with TF10 (animals 3, 4), or vaccinated with TF11 (animals 5, 6). The data illustrate the growth trajectory of the animals during the study period, providing an indicator of vaccine safety and tolerance, with the y-axis showing body weight percentage (100-200 percent) and the x-axis showing days post-vaccination (0-30 days). The graph displays two lines, one for placebo-treated animals and one for vaccinated animals, both increasing in parallel from approximately 100 percent baseline to approximately 150-180 percent overthe 30-day observation period, demonstrating normal growth in both groups with no vaccine-induced growth suppression.Docket No. 501.102. PCT
[0039] FIG.8 is a line graph showing the rectal temperature (in degrees Celsius) of individual pigs overtime (Days post vaccination) from the in vivo study described in FIGS.5-7. Animals were grouped as Mock-vaccinated (animals 1, 2), vaccinated with TF10 (animals 3, 4), or vaccinated with TF11 (animals 5, 6). The data illustrated body temperature fluctuations, providing an indicator of vaccine safety and potential reactogenicity, with the y-axis ranging from approximately 35 to 45 degrees Celsius and the x-axis showing days post-vaccination (0-30 days). Both placebo and vaccinated animals maintain stable rectal temperatures around 38-39 degrees Celsius, indicating no vaccine-induced fever or systemic illness.
[0040] FIG.9 depicts a schematic of a synthetic phage-displayed VHH library subjected to iterative rounds of biopanning.
[0041] FIG. 10A, 10B, FIG. 10C, and FIG. 10D present results from quantitative PCR (qPCR) analysis detecting SwinepoxVirus (SWPV) DNA in various samples collected from pigs at different time points post-vaccination during the in vivo study described in FIGS.5-7 and 8. Data points represented individual animals (color-coded according to treatment group, though not explicitly labeled per panel). Lower Cq (quantification cycle) values indicated higher levels of detectable viral DNA A Cq value threshold (e.g., Gf 35, indicated by the dotted line) represents the limit of detection. The panels show SWPV qPCR results obtained for serum samples (FIG. 10A); skin swab samples (FIG.10B); oral swab samples (FIG. 10C); and nasal swab samples (FIG. 10D). These data assessed the presence, persistence, and potential shedding of the vaccine vector DNA in different bodily compartments.
[0042] FIG. 11A and FIG. 11 B present results from Enzyme-Linked Immunosorbent Assays (ELISAs) measuring antibody responses in serum samples collected from pigs at different time points (Day 0, 14, 30) post-vaccination during the in vivo study described in FIGS.5-8 and 10. Data points represented individual animals that were coded by a treatment group (Mock TF10, TF11). Optical Density (OD) values at 450 nm were plotted against time. FIG. 11 A shows results from an ELISA that used Swinepox Virus (SWPV) antigen to detect SWPV-spedfic antibody levels in serum (diluted 1: 160). FIG. 11 B shows results from a control ELISA that used a porcine cell lysate antigen to assess background reactivity or non-specific binding in the serum samples. SWPV-specific antibody levels in pig serum (measured by ELISA) in FIG. 11 showed robust anti-viral antibody development by day 30, and reactivity to porcine cell lysate in FIG.11 B, as a control for SWPV ELISA on the right showed minimal reactivity and confirmed antibody specificity to viral antigens.
[0043] FIG. 11 C, FIG. 11 D, and FIG. 11 E are each a depiction detailing results from the porcine vaccine efficacy study evaluating TF10 and TF11 swinepox vaccines. Swinepox vector shedding in serum, skin, oral, and nasal swabs were quantified by qPCR and plaque assay over the 30-day post-vaccination period, the graph shows viral detection in all sample types through approximately day 14, with clearance by day 30, demonstrating limited, controlled viral replication.Docket No. 501.102. PCT
[0044] FIG. 12A, FIG. 12B, and FIG. 12C present results from ELISAs measuring specific antibody levels in serum samples collected from pigs before vaccination (Day 0 post-infection [0 dpi] and 30 days post-vaccination (30 dpi) during the in vivo study described in FIGS.5-11. Bars represent average OD values (450 nm) for each treatment group (Mock, TF10, TF11 ) and time point, with individual animals indicated (1-6). Serum dilutions are indicated in parentheses. The panels show the obtained results for ELISAs detecting antibodies against Gonadotropin-Releasing Hormone (GnRH) in FIG. 12A; FliC antigen (potentially related to the STF2 fusion partner) in FIG. 12B; and Maltose-Binding Protein (MBP) in FIG. 12C. These data illustrated the specific antibody responses generated against the target antigen and components of the vaccine fusion proteins.
[0045] FIG. 13 presents time-course microscopy images of DF1 primary chicken embryonic fibroblast cells infected with a recombinant Fowlpox virus engineered to express Green Fluorescent Protein (FWPV-GFP). The top row shows GFP fluorescence images, and the bottom row shows corresponding brig htfield images, taken at 0, 1, 2, and 3 days post-infection (dpi). The increasing green fluorescence observed overtime demonstrated successful infection of the avian cells, expression of the GFP transgene, and spread of the recombinant Fowlpox vector in vitro.
[0046] FIG. 14 is a comprehensive schematic depicting classes of immunogenic bacterial proteins employed as earners in the vaccine platform and the resulting antigen constructs. The figure depicts a stylized bacterial cell on the left, indicating the source of the carrier proteins. The figure shows three pathways branching from different protein types: (1) CRM197 (Inactive Diphtheria Toxin), labeled as a 'Toxin" source, which is fused with GnRH via chimera methodology to produce TCG13 (TF6); (2) Maltose-Binding Protein (MBP), labeled as an " Enzyme" source, which can be combined with GnRH via either fusion (producing MBP-12xGnRH, TF1) or chimera methodology (producing MG09L, an alternate designation referring to MBP-based chimerized antigens); and (3) Flagellin (STF2), labeled as a " Structural Protein" source, which is combined with GnRH via fusion to produce STF2-12xGnRH (TF7). The figure uses color coding and directional arrows to distinguish between " GnRH Chimera" (epitope grafting approach) and " GnRH Fusion" (tandem repeat approach) methodologies. Each resulting antigen construct is depicted with the bacterial protein (shown in blue) and multiple GnRH copies (shown as orange / yelbw circles or repeats).
[0047] FIG. 15 is a depiction of results of a rodent efficacy study comparing testis weight reduction across multiple vaccine candidates. The figure shows the vaccination protocol timeline at the top: initial vaccination at Week 0 with protein plus adjuvant (100 micrograms) administered intramuscularly, a booster vaccination at Week 3 with identical dose and route, and evaluation of immune response and reproductive effects at Week 8. Bebw the timeline is a bar graph displaying testis weight (in grams) on the y-axis (ranging from 0.0 to 2.5 grams) and different treatment groups on the x-axis: Control, OVA (ovalbumin control protein), Alt (alternative protein), Flagellin, MBP, and CRM197. The graph dearly demonstrates thatMBP-GnRH vaccination (labeled as " MBP-GnRH" with an arrow and annotation) resulted in a 75 percent decrease in testis weight compared to control animals, establishing MBP-GnRH as the lead candidate. Other candidates show intermediate effects on testis weightDocket No. 501.102. PCT
[0048] FIG. 16 is a depiction detailing immunological and endocrinological data from the rodent efficacy study. The figure displays the same vaccination protocol as FIG.4 (Week 0 initial vaccination, Week 3 booster, Week 8 evaluation). The figure contains three primary data panels: (1) a graph of anti-GnRH antibody levels (measured as optical density at 450 nanometers) showing dramatic elevation in MBP-GnRH12x vaccinated animals (approximately 2.5) compared to controls (approximately 0.2), representing a 14-fold increase; (2) a graph of serum testosterone concentration (in nanograms per deciliter) showing approximately 80 percent suppression in vaccinated animals (reduced from approximately 170 ng / dL to approximately 30 ng / dL); and (3) histological cross-seclions of testicular tissue comparing control animals (showing normal seminiferous tubule architecture with abundant germ cells) versus MBP-GnRH12x vaccinated animals (showing severe disruption of tubule structure with loss of germ cells and spermatids, confirming speimatogenic arrest).
[0049] FIG. 17 is a depiction of an in vitro evaluation of the rodent-specific Volepox Virus vector demonstrating species-specificity. The figure shows a detailed illustration of the Volepox Vectorparticte on the left, annotated with " Rodent vaccine vector Attenuated Volepox Virus with 11 genes deleted Engineered to Express GFP." To the right the figure shows four panels representing cell cultures from different animal species, where only the rodent shows green fluorescence indicating GFP expression and successful viral replication. This in vitro testing across multiple species confirms that the Volepox vector replicates exclusively in rodent cells, establishing species-specificity.
[0050] FIG. 18 is a depiction of an in vitro evaluation of the porcine-specific Swinepox Virus vector demonstrating species-specificity. The figure displays a stylized Swinepox Vector particle on the left annotated as " Attenuated Swinepox Virus Engineered to Express GFP." To the right are four panels representing cell cultures from different animal species: where only the porcine shows green fluorescence indicating GFP expression and successful viral replication. This in vitro evaluation confirms that the Swinepox vector replicates exclusively in porcine cells.
[0051] FIG. 19 is a depiction of preliminary safety and immunogenicity data from a porcine vaccine study with Swinepox-GnRH. The figure displays the vaccination protocol: a single intramuscular injection of Swinepox-GnRH vaccine at day 0, with evaluation of safety and immune response at day 30 post-vaccination. The figure contains two primary data panels: (1 ) a graph of body weight over 30 days post-vaccination showing parallel trajectories for placebo-treated and vaccinated animals, both increasing normally from approximately 100 percent baseline to approximately 150-180 percent of baseline weight indicating no vaccine-induced growth retardation or systemic toxicity; and (2) a bar graph of antibody detection (measured as optical density at 450 nanometers) showing antibody responses against three antigens at 0 days post-vaccination (0 dpi) and 30 days post-vaccination (30 dpi): Swinepox (viral vector antigen), Bacteria Antigen (MBP carrier protein), and Fertility Antigen (GnRH). The data show robust increases in antibody liters for all three antigens by day 30, confirming successful viral replication, antigen expression, and immune activation in vaccinated animals.Docket No. 501.102. PCT
[0052] FIG.20 is a depiction of a graph illustrating the persistence of antibody responses elicited by viral vector-based vaccines versus non-replicating protein-based vaccines, based on published epidemiological data from Amanna et al. (New England Journal of Medicine 357.19, 2007). The figure contains two panels: (1 ) the left panel labeled " Viral vector"' shows antibody titers to vaccinia virus remaining stable and elevated over many years (50-plus years), with individual serum antibody titer lines fluctuating around a plateau rather than declining precipitously; and (2) the right panel labeled " Non-replicating Protein Antigens" shows antibody titers to tetanus toxoid declining gradually over time with a half-life of approximately 11 years, illustrated by multiple serum antibody titer lines sloping downward across the age range. This comparison demonstrates that viral vector-induced antibodies persist far longer than protein-based vaccine-induced antibodies, supporting the use of poxvirus vectors for a single-dose, long-lasting contraceptive vaccine.
[0053] FIG.21 is a summary of vaccine candidates (TF1 through TF9) tested in rodent models, displaying both the antigen construct schematics and the comparative efficacy data. The figure is divided into three sections: the upper section shows schematics of each vaccine candidate, depicting the carrier protein (MBP, CRM197, STF2, or VHH) and the arrangement of GnRH peptides (shown as orange circles) within or fused to each carrier. The candidates are labeled TF1 through TF9, with their full nomenclature provided. The middle section shows " Gen2 antigens compared to control group," displaying three columns of quantitative data for each candidate: (1) Testis weight reduction (shown as downward arrows with percent changes ranging from 3 percent to 30 percent), (2) Testosterone suppression (shown as downward arrows with percent reductions ranging from 49 percentto 88 percent), and (3) Anti-GnRH antibody increases (shown as upward arrows with fold-changes ranging from 9-fold to 16-fold). The lower section indicates " Gen3 antigen trials in progress," showing that next-generation MBP-XXxGnRH variants and other improved constructs are currently under evaluation in rodent models, with results expected in March 2026.
[0054] FIG.22 is a depiction of histological cross-sections of testicular tissue from rodents vaccinated with five different vaccine candidates, demonstrating the dose-dependent relationship between antigen design and severity of testicular pathology. The figure displays six panels arranged in a 2x3 grid, each showing a hematoxylin-and-eosin stained histological section of testicular tissue: (1 ) Image A (Control) shows normal seminiferous tubule architecture with organized layers of spermatogenic cells progressing from spermatogonia at the tubule periphery to mature spermatozoa in the tubule lumen; (2) Image B (MBP-GnRH12x, TF1 ) shows severe disruption of seminiferous tubule structure with dramatic loss of germ cells, absence of spermatids and spermatozoa, and persistence of only Sertoli cells and occasional spermatogonia, representing near-complete spermatogenic arrest; (3) Image C (GnRH12x-MBP, TF2) shows severe tubular disruption similar to TF1; (4) Image D (MBP-GnRH12xmut, TF3) shows intermediate disruption with some residual germ cells; (5) Image E (MBP-lntemal GnRH12x, TF4) shows severe disruption; and (6) Image F (MBPmut-GnRH12x, TF5) shows severe disruption. These histological comparisonsDocket No. 501.102. PCT
[0055] establish that MBP-GnRH12x (TF1 ) induces the most profound spermatogenic arrest and represents the lead candidate for advancement to large animal efficacy trials.
[0056] FIG.23 is a schematic depiction comparing the genetic composition of two alternative approaches to achieving contraception: gene therapy (AAV9-GnRH nAb) and immunoconlraception (POX-MBP-GnRH). The figure is divided into two sections. The upper section depicts AAV9-GnRH nAb, a gene therapy genetic construct packaged within an adeno-assodaled virus (AAV) particle (shown as an icosahedral structure). The construct encodes the following functional elements: CBA (a constitutive promoter derived from the chicken beta-actin gene with CMV early enhancer fortissue-specific and temporally unrestricted expression), SSP (a secretory signal peptide for directing the translated protein to the secretory pathway), Kozak (a Kozak translation initiation sequence optimized for efficient translation initiation), VHH (the variable domain of a heavy-chain-only antibody, a nanobody, approximately 15 kilodaltons, directed against GnRH), WPRE (a post-transcriptional regulatory element that enhances expression and viral genome stability), and pA (a polyadenylation signal for proper transcription termination). The lower section depicts POX-MBP-GnRH, an immunocontraception construct packaged within a poxvirus particle (shown as a brick-shaped structure). This construct encodes: mH5 (an optimized poxvirus promoter for antigen expression in infected cells), SSP (a secretory signal peptide), MBP (maltose-binding protein as the bacterial antigen carrier), and GnRH (the reproductive hormone peptide, typically present in 12 tandem copies). The figure illustrates the structural differences between the two approaches and emphasizes the different delivery mechanisms and anticipated duration of antibody production.
[0057] FIG.24 is a diagram of the animal study design, showing the timeline of vaccination and sampling. The figure depicts a pig at the left, with an arrow indicating Day -1 (pre-vacdnation baseline). The main timeline shows Day 0 (vaccination: a single intramuscular injection of Swinepox-GnRH vaccine), Days 3, 7, and 14 (indicated by dots on the timeline with sample collection including blood, saliva, skin swab, and nasal swab). The timeline extends to 1 month and 2 months post-vaccination, with additional evaluations indicated. Below the vaccination timeline, a sample collection row indicates collection of blood samples at specified timepoints (shown with collection tubes). A vitals row indicates daily measurement of temperature and weight and daily observation for skin rash and pox lesions. An assay row indicates the types of analysis performed, including GnRH ELISA (to measure anti-GnRH antibodies), SWPV Plaque assay and SWPV qPCR (to quantify viral shedding and replication), and various hormone and cytokine measurements (Progesterone ELISA Testosterone ELISA IFNg and IL4 ELISA to assess immune response type).
[0058] FIG.25 is a depiction of ALVAC-GFP infected MyoK9 cells.
[0059] FIG.26 is a depiction of plots of GFP expression intensity for different promoters in DF-1 cells infected with ALVAC and MyoK9 cells infected with ALVAC.Docket No. 501.102. PCT
[0060] FIG.27 is a depiction of GFP expressions ALVAC-GFP at a low infectious dose (50 PFU) across a diverse panel of cell lines including DF-1 (avian fibroblasts), U-2 OS (human osteosarcoma), PK-15 (porcine kidney), Vero (African green monkey kidney), MDCK (canine kidney), A549 (human lung carcinoma), F81 (feline kidney), and 293T / 17 (human embryonic kidney).
[0061] FIG.28 is a schematic diagram and bar graph illustrating the design and composition often vaccine constructs tested in rodent immunocontraceptive efficacy studies. The diagram shows the modular protein architecture of each vaccine, including carrier proteins (MBP, STF2, TF, VHH) and tandem wild-type GnRH epitope repeats. The bar graph presents testis weight changes (as percent reduction relative to mock control) for each vaccine group, ranging from 1 % increase (VHH-GnRH-206, AAV9-VHH) to 79% reduction (MG09L). The figure demonstrates construct-dependent efficacy ofcovalent GnRH fusions for immunocontraceptive activity.
[0062] FIG.29 is a box-and-whisker plot comparing absolute testis weight (in grams) across all vaccine groups at day 56 postvaccination. The plot displays the distribution of testis weights for the mock control group (mean ~1.6 g) and nine vaccine groups, with an overlay of individual data points. The figure illustrates the dose-dependent and construct-dependent reduction in gonadal mass, with MG09L (TF9-B), MBP-GnRH-12x (TF7), and MG10 (TF9-C) achieving the most pronounced atrophy (median -0.4- 0.5 g), while VHH-containing constructs lacking integrated GnRH (TF12, TF13) fail to suppress testis growth (median -1.4-1.6 g).
[0063] FIG.30 is a composite figure showing three elements: (i) a visual representation of testis morphology across mock and vacdne-treated groups at day 56, displaying gross atrophy in vaccinated animals relative to control; (ii) a schematic key identifying each vaccine group (A through J) and corresponding construct identifier; and (iii) a scatter pbt with error bans quantifying mean testis weight and variance for each group. The figure emphasizes the dramatic macrcrmorp hobgical and measurable quantitative effect of anti-GnRH immunization on gonadal devebpment
[0064] FIG.31 is a twopanel figure showing body weight asafanction of post-vaccination time. The upperpanel displays body weight (% of baseline) as a continuous line pbt for each vaccine group tracked fiom vaccination (day 0) through day 60, with vaccination events marked (arrows at days 0 and 20). All groups converge to approximately 210-240% of baseline body weight by day 60, indicating normal growth rates and absence of systemic vaccine toxicity. The lower panel presents absolute body weights as a scatter plot with error bars for each group, demonstrating equivalent final body mass across all treatments (150-275% baseline equivalent), validating that selective reproductive suppressbn was achieved without generalized wasting or immunosuppression.
[0065] FIG.32 is a scatter pbt of bbod serum testosterone levels (in ng / dL) at day 56 for all vaccine groups, with individual data points and group means. The mock control group shows baseline testosterone in the 100-300 ng / dL range; vaccinated animals receiving GnRH-fusion proteins (MBP-GnRH-12x, TCG13, STF2-GnRH-12x, MG09, MG09L, MG10, MG10L) show testosterone levels at or bebw the assay limit of detection (<5 ng / dL), representing 100% suppression. Negative control vaccinesDocket No. 501.102. PCT
[0066] (VHH-GnRH-206 without integrated GnRH, AAV9-VHH) show only partial suppression (27-67%), highlighting the functional requiiementfor covalent GnRH epitope presentation. The figure provides quantitative evidence of hormonal suppression as a primary endpoint
[0067] FIG.33 presents two ELISA time-course graphs measuring antibody kinetics in immunized animal sera. The left panel shows anti-MBP (maltose-binding protein) antibody responses (optical density at 450 nm) over days post-immunization (DPI: 0, 20, 0, 60) for representative vaccine groups. The right panel shows parallel anti-GnRH antibody responses overthe same timeframe. The data demonstrate differential immunogenicity of vaccine earners: TCG13 and MG12 induce high anti-GnRH responses with minimal MBP cross-reactivity, whereas earlier designs (MBP-GnRH-12x) showed elevated anti-MBP responses. Notably, blood sera at day 56 were diluted 1: 1280 and cerebrospinal fluid (CSF) was negative for both anti-MBP and anti-GnRH antibodies, excluding evidence of autoimmune breach of the blood-brain barrier. The figure illustrates vaccine-carrier selectivity and the refinement of platform designs to prioritize GnRH-spedfic immunity while minimizing adjuvant-directed responses.
[0068] FIG.34 is a composite figure summarizing vaccine construct design (left, showing GnRH repeat stoichiometry and carrier protein architecture forfive representative vaccines) and four box-and-whisker plots (right) depicting quantitative endpoints at days 35 and 56. The four panels display: (1) testis weight (grams), (2) serum testosterone (ng / dL), (3) anti-GnRH ELISA (OD 450 nm), and (4) anti-MBP ELISA (OD 450 nm). The figure integrates structural design, hormonal suppression, and antibody selectivity into a single overview, demonstrating that optimization of epitope repeat number (9* vs. 10x vs. 12x) and carrier scaffold (MBP vs. STF2) yields construct-dependent improvements in GnRH-specific immunity with reduced carrier cross-reactivity.
[0069] FIG.35 is a comprehensive summary table displaying vaccine construct design, quantitative efficacy parameters, and immunological readouts for all nine vaccines tested plus a reference OVA-GnRH control. Rows correspond to vaccine candidates (MBP-GnRH-12x through OVA-GnRH); columns display: (i) construct schematic (showing earner protein, GnRH repeats, and flanking domains), (ii) testis weight change (% reduction vs. mock), (iii) testosterone reduction (% suppression), (jv) anti-GnRH antibody titer (fold-increase), and (v) anti-MBP / OVA antibody titer (fold-increase). The table synthesizes Figures 28-34 into a single comparative view, enabling rapid identification of lead candidates (MG09L, MG10, MBP-GnRH-12x) and demonstrating that the platform is adaptable for rapid antigen discovery, with predictable structure-activity relationships. The legend and table footnotes define test conditions (ELISA day 35, TRT and testis collection day 56) and establish the scientific basis for platform modularity and future vaccine development against heterologous antigens.
[0070] FIG.36 is a study protocol summary for the Volepox virus infectivity evaluation in Sprague Dawley rats. The figure tabulates the experimental design including: pathogen identity (Volepox Virus D-11 expressing firefly luciferase, which establishes the organizational framework for the safety and replication study described in Figures 37-42.Docket No. 501.102. PCT
[0071] FIG.37 presents two dual-axis plots of body weight change throughout the 6-day acute phase of the Volepox infectivity study. The left panel shows mean body weight change in grams (y-axis) against days post-infection (0-6), with separate lines for each dose group, wherein all groups gain 25-35 g of body weight by day 6, with no dose-dependent suppression of growth. The right panel displays the same data as percent change from baseline weight (100% at day 0), showing all groups converge to ~120-125% by day 6. Scatter plots with individual animal data points are overiaid on the mean line plots. The figure demonstrates that the attenuated Volepox vector does not elicit acute weight bss, malaise, or systemic toxicity even at the highest challenge dose.
[0072] FIG.38 is the complementto FIG.37, presenting body weight change data in alternative graphical formats to emphasize doseindependence of growth suppression. The upper panel replicates the group mean line plot (grams) for clarity; the lower panel shows percent change from baseline. Individual animal data are plotted as discrete colored points overiaid on group means, with error bars (typically standard enor or confidence intervals) indicating inter-animal variability within each group. The figure affirms that infection with attenuated Volepox virus at any of the tested doses does not perturb normal post-infection growth trajectories, supporting the conclusion that viral replication occurs without systemic virulence.
[0073] FIG.39 presents rectal body temperature (% of original / baseline) overthe 6-day post-infection period. T e upper panel displays mean temperature as percent of day-0 baseline for each dose group as a continuous line plot; all groups remain at -100% baseline temperature (37.8 - 38.3°C equivalent) with negligible fluctuation across days 0-6, indicating absence of fever. The lower panel shows individual animal temperature data pointe as a scatter plot, with all values clustering tightly around the 100% line. Error bans (if present) indicate minimal within-group variance. The figure establishes that the Volepox vector does not induce febrile response or hypothermia excluding evidence of acute systemic infection or inflammatory disease at any of the challenge doses tested.
[0074] FIG.40 is an in vivo bioluminescence imaging panel for day 2 post-infection. The left side displays a composite of optical images collected 15 minutes post-luciferin injection (10 mUkg IP) for representative animals from the PBS-mock and 105PFU groups. Images show two animal orientations per group (dorsal and ventral views) Bioluminescent signal was localized to the injection site (right hindquarters) and peritoneal / abdominal regions.
[0075] FIG.41 is the parallel bioluminescence imaging panel for day 5 post-infection at the 15-minute post-luciferin timepoint Optical images (left) show representative PBS-mock and Volepox-infected animals with visible bioluminescent signal localized to the injection site and rostral spread into the abdominal region, consistent with viral replication spreading from the initial IM injection site.
[0076] FIG.42 presents a delayed (3-hour post-luciferin injection) imaging timepoint at day 5 to assess signal retention and clearance kinetics. Optical images (left) show representative animals with a bioluminescent signal that remains prominent in infected tissues despite the extended time since luciferin administration. The elevated 3-hour signal relative to mock controls and relative to typicalDocket No. 501.102. PCT
[0077] luciferin phaimacokinetics (>90% substrate clearance expected) indicates sustained, high-level luciferase production fiom actively replicating virus.
[0078] FIG.43 depicts antigen plate-binding ELISA confirming adsorption of FSHp at 10 pg / mL and 1 pg / mL coaling concentrations, and adsorption of GnRH at 10 pg / mL but not at 1 pg / mL, in BioRad coating buffer (pH 7.8-8.2), as detected with anti-His-HRP. FIG.44 depicts panning enrichment for GnRH, including a phage ELISA showing preferential binding to GnRH-OVA versus OVA, and an OVA-subtracled signal-difference pbt supporting target-specific enrichment
[0079] FIG.45 depicts panning enrichment for FSH following two additional rounds on FSHb-His with BSA-His negative selection, with phage ELISA showing significant FSHp enrichment and minimal BSA-His background.
[0080] FIG.46 depicts an ELISA screen of 94 individual colonies for GnRH on GnRH-OVA versus OVA plates, including raw signal, foldchange, and difference plots used to nominate clones for sequencing.
[0081] FIG.47 depicts the ELISA screen of 94 individual colonies for FSH on FSHB-His versus BSA-His plates, including raw signal, fold-change, and difference plots.
[0082] FIG.48 depicts a healmap of NGS-derived top cluster percentages across panning roundsfor GnRH (Rounds 3, 4, 5-OVA-GnRH, 5-OVA 6-OVA-GnRH, and 6-OVA), illustrating round-over-round enrichment of specific CDR dusters.
[0083] FIG.49 depicts a heatmap of NGS-derived top duster percentages across panning rounds for FSHfJ (Round 3 and Round 4 on pep 1, and Round 3 and Round 4 on FSHb-His), illustrating enrichment of specific CDR dusters when panning was repeated on the full-length His-tagged protein.
[0084] DETAILED DESCRIPTION
[0085] The present disclosure provides a platform herein, that is versatile and based on recombinant poxviruses for addressing critical needs in animal health and population management Specifically, the platform herein relates to the development and use of engineered poxvirus vectors, particularly species-specific vectors like Swinepox Virus (SWPV), to deliver polypeptides capable of indudng immunocontraception for humane population control and / or deliver heterologous antigens for vaccination against infectious diseases, such as African Swine Fever Virus (ASFV). Certain embodiments envision vectors capable of transmission between animals, offering highly scalable solutions for wildlife management
[0086] The platform herein can be an immunocontraceptive vacdne platform that induces long-term infertility in vertebrate pest species through a single administration. The platform harnesses the innate and adaptive immune systems to generate robust antibodies against gonadotropin-releasing hormone (GnRH), a critical reproductive hormone in all vertebrates.Docket No. 501.102. PCT
[0087] An immunocontraceptive vaccine platform that harnesses an animal's own immune system to suppress its reproductive capacity through generation of antibodies against a reproductive hoimone, rather than employing lethal toxins or repeated interventions. The platform comprises a protein antigen and a vectorfor encapsulating the protein antigen characterized as having a singledose long-teim efficacy, species-specificity eliminating non-target harm, oral delivery enabling landscape-scale deployment; antibody durability, environmental safety without secondary poisoning risks, and regulatory compatibility through use of established poxvirus vaccine technology.
[0088] FIG. 1 B illustrates the reproductive hormone cascade showing how GnRH from the hypothalamus regulates gonadotropins (FSH and LH) from the anterior pituitary, which in turn regulate germ cell development and reproductive hormone production in the gonads (testes and ovaries). By generating anti-GnRH antibodies, the vaccine blocks this cascade at its origin, preventing FSH and LH secretion and resulting in suppression of germ cell development and reproductive hormone synthesis. These anti-GnRH antibodies circulate in the bloodstream and neutralize native GnRH, thereby interrupting the hormonal cascade necessary for reproduction and resulting in persistent infertility.
[0089] The platform herein is directed to recombinant poxvirus vectors, compositions, and methods for inducing animal immune responses, including vaccination against infectious diseases and for immunocontraception. More particularly, poxviruses (e.g., species-specific, attenuated Swinepox Virus) are engineered to express desired polypeptides. For instance, poxviruses express: African Swine Fever Virus (ASFV) antigens (e.g., CP204L) for protective immunity in swine are expressed; or immunocontraceptive antigens, such as GnRH (often fused with carriers like MBP or STF2), to induce infertility in species such as swine, canids, and felids for humane population control. Dual-purpose vectors expressing both disease and immunocontraceptive antigens, and transmissible vectors for wildlife management, are also described. The platform herein covers related vaccine / immunocontraceptive compositions and their use.
[0090] Recombinant Poxvirus Vectors
[0091] The platform herein leverages members of the Poxviridae family, specifically viruses within the Chorabpoxwrtoae subfamily, as versatile vectors for delivering heterologous genetic material to target animal cells and hosts. Poxviruses offer several distinct advantages for vector development Poxviruses are relatively large, double-stranded DNA genomes, typically ranging from approximately 130 to 375 kilobase pairs depending on the genus and species, provide substantial capacity for stably accommodating multiple large foreign gene inserts or complex expression cassettes without significantly compromising viral viability or function. Furthermore, poxviruses replicate exclusively within the cytoplasm of infected host cells, a feature that significantly enhances the safety profile of vectors comprising poxviruses, compared to vectors that integrate into the host genome (such as retroviruses or lenti viruses) by inherently avoiding the risk of insertional mutagenesis. Many poxviruses are known to be highly immunogenic, capable of eliciting robust and durable immune responses, including both neutralizing antibodies (humoralDocket No. 501.102. PCT
[0092] immunity) and cytotoxic T lymphocyte (CTL) responses (cellular immunity), which are often crucial for effective vaccination against complex pathogens or for breaking tolerance to self-antigens in immunocontraceptive strategies. Additionally, poxvirus virions are generally known fortheir considerable environmental stability compared to many other enveloped viruses, a property that can be advantageous for vaccine formulation, storage, and potential field deployment, including oral bait delivery systems forwidlife.
[0093] The platform herein involves the selection and utilization of poxvirus species or strains that exhibit natural host-range restriction or species-specificity, thereby tailoring the vectorto the intended target animal population. This approach maximizes safety by limiting productive replication and potential pathogenicity primarily to the target species, minimizing risks to non-target animals, including humans, and the environment For applications directed towards swine, including domestic pigs (Sus scrofa domesticus), wild boar (Sus scrota), and feral hog populations, SwinepoxVirus (SWPV), a member of the Suipoxms genus, represents a particularly advantageous vector choice due to its well-established natural host restriction to suids. The successful engineering and preliminary in wo evaluation of recombinant SWPV vectors detailed herein (e.g., FIGS.3-12) validate the utility of SWPV as a vector platform for swine. Extending this principle, other poxviruses with demonstrated or potential host restrictions can be empbyed for devebping species-specific interventions in diverse animal populations. For instance, Myxoma virus, a Leporipoxvirus, may be adapted for targeting rabbits and potentially other lagomorphs. Capripoxviruses, such as Sheeppox virus, Goalpox virus, or Lumpy skin disease virus, offer potential vectors for ruminants, such as sheep, goals, and catle. Avipoxviruses, including Fowlpox virus, are well-suited for avian species. Furthermore, vectors based on poxviruses specific to, orengineerabb for specificity towards, other target groups such as canids (e.g., dogs, coyotes, foxes), felids (e.g, domestic cats, feral cats), rodents (e.g., rats, mice), cervids (e.g., deer), camelids, raccoons, skunks, mustelids, or other wildlife species fell within the scope of this invention. The selection may also involve choosing specific strains or isolates within a poxvirus species, as different strains can exhibit variations in virulence, immunogenicity, replication characteristics, and amenability to genetic manipulation.
[0094] To further enhance the safety profile, particularly for in wo applications such as vaccination or biobgical control, the poxvirus vectors utilized in the platform herein are preferably atenuated compared to their corresponding wild-type parental strains. Attenuation refers to the reduction or elimination of the virus's capacity to cause significant disease in the target host, while ideally preserving sufficient replication competence to ensure adequate expression of the heterobgous antigen(s) and induction of a robust immune response. Attenuation can be achieved through various established methodologies known in the art. These include empirical methods like serial passage of the virus in non-standard host cells or under altered culture conditions, or random chemical mutagenesis followed by selection for less virulent phenotypes. However, more precise and preferred methods involve targeted genetic modification of the poxvirus genome. This frequently involves the deletion or inactivation of specific viral genes known to contribute to virulence, pathogenicity, or host immune evasion.Docket No. 501.102. PCT
[0095] Examples of such genes often targeted for deletion in poxviruses include immunomodulatory genes (e.g, those interfering with interferon pathways, encoding homologs of cytokine receptors like TNF receptors, producing chemokine-binding proteins, or inhibiting complement pathways), host range genes that may restrict replication in certain cell types or species, genes involved in viral nucleotide metabolism (e.g, thymidine kinase (TK), which is also a common site for heterologous gene insertion), or genes encoding inhibitors of apoptosis. Alternatively, or additionally, attenuation can result from the insertion of foreign expression cassettes into non-essential regions of the viral genome, thereby disrupting endogenous viral genes at the insertion site. The degree of attenuation can exist on a spectrum, ranging from mildly attenuated strains that still replicate efficiently / h wo to highly attenuated strains with severely restricted replication. An alternative embodiment involves the use of replication-deficient poxvirus vectors, such as Modified Vaccinia Ankara (MVA) or certain Avipoxvirus vectors like ALVAC, which are incapable of completing a full replication cycle in most mammalian host cells. While potentially offering an enhanced safety profile, replication-deficient vectors might induce different immune kinetics or require larger doses or prime-boost regimens compared to replication-competent attenuated vectors. The specific SWPV vectors described in the examples herein (e.g., TF10, TF11 ) are designed and characterized as attenuated but replicalion-competent vectors, with preliminary safety supported by / h vw data showing normal growth (FIG.7) and lack of fever (FIG.8) in vaccinated pigs. The choice between replication-competent attenuated and replication-deficient vectors depends on the specific application, target species, safety requirements, and desired immune outcome.
[0096] Heterologous Polypeptides and Antigens
[0097] A feature of the recombinant poxviruses of the platform herein is the amenability to genetic engineering to express one or more heterologous polypeptides, thereby conferring novel biological functions upon the vector. These polypeptides are "heterologous" by virtue of not being naturally encoded by the parental poxvirus strain used for vector construction. The selection of the specific heterologous polypeptide(s) dictates the intended application of the resulting vector, whetherfor inducing protective immunity against infectious agents, modulating host reproductive physiology for immunocontraception, serving as markers, or enhancing immune responses. Expression cassettes encoding these polypeptides can be inserted at single or multiple distinct lod within the poxvirus genome.
[0098] For applications focused on vaccination against infectious diseases, particularly African Swine Fever Virus (ASFV) in swine, the recombinant poxvirus vectors are engineered to express one or more ASFV antigens. The goal is to elicit protective immune responses, encompassing both humoral immunity (e.g., neutralizing antibodies) and cellular immunity (e.g., antigen-specific T-lymphocyte responses, including CD8+cytotoxb T lymphocytes), which are believed to be critical for controlling ASFV infection. The selection of ASFV antigens can be based on empirical evidence from previous vaccination studies, bbinfoimatic predictions of immunogenicity, or knowledge of ASFV biobgy. Antigens may include structural proteins (involved in virion assembly andDocket No. 501.102. PCT
[0099] structure), non-structural proteins (involved in viral replication, host interaction, or immune evasion), or proteins expressed at different stages of the viral lifecycle (early, intermediate, or late). Given the complexity of ASFV and the challenges in achieving robust protection, preferred embodiments employ a multivalent strategy, wherein the vector coexpresses a plurality of different ASFV antigens simultaneously. This approach aims to broaden the immune repertoire targeted, potentially enhancing the breadth and efficacy of protection, including against genetically diverse ASFV strains (e.g., different genotypes, such as the relevant Genotype I and II viruses). Exemplary ASFV antigens suitable for inclusion, individually or in combination, comprise, but are not limited to, well-characterized immunogens like p30 (encoded by CP204L), p54 (E183L), the major capsid protein p72 (B646L), the hemagglutinin CD2v(EP402R), structural protein pp62 (B602L), the polyprotein pp220 (CP530R, precursor of p15, p34, p37, p8), as well as other potential targets such as E199L, EP153R, F317L, members of multigene families like MGF360 or MGF505 (e.g., MGF505-5R), p10 (K78R), p12 (061 R), or other known or predicted B-cell orT-cell epitopes or full-length proteins derived from the ASFV genome. Specific embodiments detailed herein involve recombinant SWPV vectors designed to express either a five-antigen cocktail (CP204L, E183L, EP402R, B646L, B602L) or an eight-antigen cocktail (adding E199L, EP153R, F317L, MGF505-5R). Such multivalent constructs are designed to elicit comprehensive immunity and provide robust protection against virulent ASFV challenge in susceptible swine hosts. Antigens may be expressed as individual polypeptides, or alternatively, as fusion proteins or polyprotein precursors that are subsequently processed, or as epitope strings comprising multiple B-cell and / or T-cell epitopes concatenated together.
[0100] For applications directed towards immunocontraception, the vectors are engineered to express polypeptides that function as immunocontraceptive antigens. These antigens can be: typically host "self1proteins or hormones involved in reproduction, and the vector-induced immune response against them disrupts normal reproductive processes, leading to infertility (as depicted schematically in FIG.2). A primary and widely applicable target is Gonadotropin-Releasing Hormone (GnRH), a decapeptide hormone central to the hypothalamic-pituitary-gonadal axis in mammals. GnRH stimulates the release of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) from the pituitary, which are essential for gametogenesis and sex steroid production in both males and females. Due to the small size and potential for poor immunogenicity of GnRH, GnRH is typically expressed and presented to the immune system as part of a larger molecule, most commonly as a fusion protein. GnRH is operably linked, often via genetic fusion optionally including flexible linker sequences, to an immunogenic earner protein or an adjuvant molecule that enhances T-cell help and overall immune recognition. Exemplary canier / adjuvant fusion partners demonstrated herein include bacterial Maltose-Binding Protein (MBP) and a flagellin derivative (STF2, likely derived from Salmonella Typhimurium FliC), as shown in the SWPV constructs TF10 (STF2-GnRH) and TF11 (MBP-GnRH) (FIG.4, FIG.6, FIG. 12). Other suitable carrier proteins include, but are not limited to, Keyhole Limpet Hemocyanin (KLH), fragments of bacterial toxins (e.g., tetanus toxoid, diphtheria toxoid), viral capsid proteins (which may form virus-like particles), or even strongly immunogenic proteins derived from the poxvirus vector itself. Multiple copies of GnRH may be included within a single fusion protein or expressed from separateDocket No. 501.102. PCT
[0101] cassettes to increase antigen density. The GnRH sequence itself may be the native sequence for the target species (e.g., porcine GnRH, canine GnRH, feline GnRH) or a consensus sequence or modified sequence designed for broader reactivity or enhanced stability / immunogenicity. Another major class of immunocontraceptive targets includes Zona Pelludda (ZP) proteins These glycoproteins (e.g., ZP1, ZP2, ZP3, ZP4) form the extracellular matrix surrounding the mammalian oocyte and play critical roles in speim binding and fertilization. Antibodies directed against ZP proteins, particularly ZP2 and ZP3, can effectively block fertilization, primarily providing female-specific contraception. As with GnRH, ZP antigens are often expressed as fusion proteins or displayed on particulate structures to enhance immunogenicity. Additional potential targets for immunocontraception accessible via this vector platform include the gonadotropins LH or FSH themselves (or specific subunits), receptors for reproductive hormones (e.g, GnRH receptor, LH receptor, FSH receptor, estrogen receptors, androgen receptors), enzymes critical for steroid hormone synthesis (e.g, aromatase), inhibin or activin, orspeim-specific antigens (e.g, SPAM1 / PH-20, Izumol, fertilin). The optimal choice of immunocontraceptive antigen and its presentation strategy (e.g, fusion partner) depends heavily on the target species, the desired duration and reversibility of effect, and whether contraception is intended for males, females, or both.
[0102] A particularly powerful application of the versatile poxvirus vector system of the platform herein involves the creation of dualpurpose constructs. Leveraging the large coding capacity of poxviruses, a single recombinant vector can be engineered to concurrently express both antigens derived from an infectious pathogen (e.g, one or more ASFV antigens) and one or more immunocontraceptive antigens (eg, a GnRH fusion protein). Such dual-purpose vectors offer an integrated approach to managing interconnected problems, particularly in wildlife populations that act as disease reservoirs and also experience overpopulation challenges. For instance, a dual-purpose SWPV vector administered to wild boar could simultaneously contribute to reducing ASFV prevalence within the reservoir population (protecting domestic pigs) and limiting boar reproductive rates (mitigating ecological and agricultural damage). Similar strategies could be envisioned for other species, such as a vector expressing rabies virus glycoprotein and a GnRH fusion protein for controlling rabies and population numbers in feral dogs or coyotes.
[0103] Beyond antigens for vaccination or immunocontraception, the recombinant poxvirus vectors of the platform herein may also be engineered to express other types of heterologous polypeptides. These can include reporter genes, such as Green Fluorescent Protein (GFP) as demonstrated herein (FIG.3), or otherfluorescent proteins (e.g, RFP, mCherry), luciferase, or betagalactosidase. Reporter genes are valuable tools for vector development allowing easy tracking of viral infection and gene expression in vitro and potentially in vw, facilitating titration, monitoring spread, and optimizing vector design. Furthermore, vectors can be engineered to express immunostimulatory molecules designed to enhance or shape the immune response elicited by the primary antigen(s). Examples include cytokines (e.g, lnterleukin-2 (IL-2), IL-12, IL-15, Interferon-gamma (IFN-y), Granulocyte-Macrophage Colony-Stimulating Factor (GM-CSF)), chemokines, co-stimulatory molecules (e.g, B7.1 / CD80,Docket No. 501.102. PCT
[0104] B7.2 / CD86), ligands forToMke receptors (TLRs) or other pattern recognition receptors, or danger signals like heat shock proteins (HSPs). Coexpression of such molecules can serve as a genetic adjuvant, potentially increasing the magnitude, altering the Th1 / Th2 balance, or improving the memory characteristics of the immune response to the coexpressed vaccine or immunocontraceptive antigen. Additionally, vectors might incorporate selection markers (e.g, drug resistance genes or metabolic enzymes) to facilitate the isolation and purification of recombinant viruses during the development phase, although such markers are often removed or avoided in final constructs intended for in wo use.
[0105] Genetic Constructs and Engineering
[0106] The construction of the recombinant poxvirus vectors of the platform herein, as described herein, can involve the design and insertion of specific genetic elements into the parental poxvirus genome. For example, an expression cassette of the platform herein contains the sequences to drive the expression of the desired heterologous polypeptide(s) within the infected cytoplasm of the host cell. In the platform herein, the expression cassette comprises, at minimum, a promoter sequence operably linked to a coding sequence for the heterologous polypeptide, followed by a transcriptional termination signal that is functional in the context of the poxvirus replication cycle. Multiple expression cassettes, potentially encoding different antigens or polypeptides, can be inserted at one or more distinct loci within the viral genome to generate multivalent or multi-functional vectors.
[0107] Promoter sequences are critical for controlling the timing and level of heterologous gene expression by the platform herein. Poxvirus promoters are generally utilized, and these can be selected based on their temporal activity during the viral replication cycle (Ze, early, intermediate, or late promoters) or their inherent strength. Early promoters (e.g., the well-characterized Vaccinia virus P7.5 promoter) are active before viral DNA replication begins, utilizing host cell factors and early viral enzymes. Late promoters (e.g., the Vaccinia virus P11 K promoter) typically require viral DNA replication and late viral transcription factors for activity, often driving higher levels of protein expression, which can be advantageous for antigen production. Intermediate promoters also exist In addition to natural promoters, synthetic promoters or modified natural promoters can be employed to achieve specific desired expression levels or characteristics. For example, strong synthetic early / late promoters (sE / L) have been developed for high-level constitutive expression throughout the infection cycle. An exemplary promoter referenced herein is the mH5 promoter (FIG.6), chosen for its suitable strength and activity profile within the SWPV vector system. The choice of promoter can influence the immunogenicity of the expressed antigen and the overall characteristics of the vector. In some embodiments, inducible promoter systems, responsive to external stimuli (e.g, tetracycline-responsive systems adapted for cytoplasmic function), may be incorporated for controlled gene expression, although this is less common for poxvirus vaccine vectors. For expression of multiple polypeptides from a single insertion site, strategies can include: using divergent promoters flanking the insertion, incorporating internal ribosome entry site (IRES) elements (though IRES function can be variable in poxvirus systems), or expressing polyproteins that are subsequently cleaved, potentially using self-cleaving 2A peptide sequences.Docket No. 501.102. PCT
[0108] The coding sequences correspond to the heterologous polypeptides intended for expression. These sequences encode the selected ASFV antigens, immunoconfraceptive polypeptides (e.g, GnRH, ZP proteins), fusion partners or carriers (e.g, MBP, STF2 / FHC), or other desired proteins like reporters or immunomodulators, as detailed herein. These DNA sequences can be obtained by cloning from source organisms, synthesized chemically based on known sequences, or derived fiom existing plasmids. To optimize protein expression levels in the target host species, codon optimization of the coding sequence is often performed. For example, when expressing antigens in an SWPV vector for use in pigs, the coding sequence may be optimized to reflect the codon usage bias of Sus scrota. Coding sequences may also be engineered to include additional elements, such as signal peptides (e.g, the CD33 signal peptide mentioned in FIG.6) to direct the expressed protein towards the secretory pathway for surface display or secretion, which can influence immunogenicity. Alternatively, proteins may be designed for cytoplasmic localization or targeting specific organelles. Epitope tags (e.g, His-tag, HA-tag, Myc-tag) can also be fused to the coding sequence to facilitate detection, purification, or immunological analysis of the expressed protein.
[0109] Heterologous expression cassettes of the platform herein are typically inserted into non-essential regions of the poxvirus genome. Insertion into such regions minimizes the disruption of genes vital for viral replication, while often contributing to vector attenuation if the insertion site disrupts a non-essential gene contributing to virulence or host interaction. The thymidine kinase (TK) gene locus (e.g, the J2R gene in Vaccinia virus) is a widely used and well-characterized non-essential site for insertion in many poxviruses, and selection for TK-negative recombinants can be achieved. Other known non-essential lod, such as the hemagglutinin (HA) gene bcus in Vaccinia virus (A56R), intergenic regions, or sites of specific gene deletions created for attenuation purposes, can also serve as insertion sites. For multivalent vectors expressing multiple antigens, expression cassettes can be inserted into multiple distinct non-essential loci distributed across the genome. The specific non-essential loci suitable for insertion in SWPV or other species-specific poxviruses used herein may be identified based on genomic annotation, comparative genomics, or empirical testing.
[0110] The primary method for introducing the expression cassette into the poxvirus genome of the platform herein is homologous recombination. This typically involves constructing a transfer plasmid (or transfer vector) in E. cdi. This plasmid contains the complete expression cassette® flanked by relatively bng stretches of DNA sequences (termed "flanking arms" or "homology arms") that are identical (homologous) to the viral DNA sequences immediately upstream and downstream of the intended insertion site within the poxvirus genome. Susceptible host cells (e.g, PK-15 cells for SWPV) are then transfected with this transfer plasmid using standard methods (e.g, lipid-based transfection, electroporation). Subsequently, or concurrently, these cells are infected with the parental poxvirus strain (which may already be attenuated). Inside the co-infected / transfected cell, homologous recombination occurs between the flanking arms on the plasmid and the corresponding sequences in the replicating viral genome, leading to the replacement of the endogenous viral sequence at the target locus with the expression cassette fromDocket No. 501.102. PCT
[0111] the transfer plasmid in a subset of the progeny virions. While standard homologous recombination is often efficient enough in poxvirus systems, alternative methods like CRISPR / Cas9-assisted recombination could potentially be adapted to enhance efficiency or precision, although they are less routinely used compared to plasmid-based homologous recombination for poxviruses.
[0112] Following recombination, selection and purification strategies are employed to isolate the desired recombinant viruses tram the much larger background population of non-recombinant parental viruses. Selection can be based on the phenotype conferred by the insertion orthe disruption of the targeted gene. For example, insertion into the TK gene allows for selection ofTK-negative recombinants by plaquing in the presence of bromodeoxyuridine (BrdU). Alternatively, the transfer plasmid can incorporate a transient dominant selection marker, such as a gene conferring resistance to a drug (e.g, neomycin resistance, mycophenolic acid resistance) or a gene encoding a readily screenable marker protein (e.g, GFP, beta-galactosidase detected with X-gal). After initial selection pressure enriches for recombinants (which may cany both the desired insert and the marker), subsequent passages without selection can allow for resolution via recombination to remove the marker cassette, leaving only the desired heterologous gene insert Expression of a reporter gene (e.g, GFP) corinserted with the gene of interest can also facilitate identification and purification of recombinant plaques based on fluorescence. Regardless of the selection method, multiple rounds of plaque purification are crucial to ensure the resulting virus stock is clonal ( / .e, derived from a single recombinant virus particle) and free from contaminating parental virus. Typically, three to six or more rounds of picking well-isolated plaques and re-plaq uing are performed. Limiting dilution can also be used as a purification method. (See FIG. 11 C, FIG. 11 D, and FIG.11 E.)
[0113] Finally, rigorous verification of the purified recombinant virus stock is performed. Correct insertion of the expression cassette at the intended locus and the absence of unintended rearrangements may be confirmed using PCR genotyping with primers flanking the insertion site or internal to the cassette. The precise DNA sequence of the inserted cassette and the flanking viral regions is often verified by Sanger sequencing of PCR amplicons. For comprehensive quality control and to confirm the overall integrity of the recombinant genome, whole-genome sequencing (WGS), often using next-generation sequencing platforms like Illumina technology, is highly recommended, particularly for constructs intended for in wo use or clinical development In addition to genomic verification, functional verification, confirming that the inserted cassette leads to the expression of the intended heterologous polypeptide at expected levels, is performed using techniques like Western blotting (FIG.4), immunofluorescence assays (FIG.3, adapted for specific antigen), or functional assays relevant to the expressed protein.
[0114] Generation, Production, and Characterization of Recombinant Viruses
[0115] Following the successful genetic engineering and isolation of clonal recombinant poxvirus isolates of the platform herein, the subsequent steps involve: the generation of viral stocks, the production of the viral stocks at appropriate scales; and rigorous characterization to ensure identity, purity, potency, stability, and safety. The specific procedures and scale of production may varyDocket No. 501.102. PCT
[0116] depending on whetherthe virus is intended for research purposes, pre-dinical in wo studies, or eventual large-scale field deployment or commercial veterinary use, with the latter requiring adherence to stricter quality control and manufacturing standards, for example, Good Manufacturing Practices or GMP-like standards.
[0117] The recombinant poxviruses of the platform herein can be typically generated and propagated by infecting susceptible host cell lines in vitro. The choice of cell line depends on the specific poxvirus vector being used. For recombinant SWPV, suitable cells include primary porcine cells or established porcine cell lines such as PK-15 porcine kidney cells, SK6, ST swine testicle cells, primary porcine nasal epithelial cells, or porcine macrophage-derived cell lines, reflecting the natural tropism of the virus as demonstrated in FIG.3. For other species-specific vectors, appropriate cell lines permissive forthat virus's replication would be used, such as RK13orVero cells for Myxoma virus, chicken embryo fibroblasts (CEFs)or avian cell lines like QT6for Avipoxviruses, or Vero cells or specific ruminant cell lines for Capripoxviruses. For production intended for veterinary or clinical applications, cell lines must be well-characterized, often obtained tram certified cell banks, and demonstrated to be free of endogenous or adventitious agents. Cells can be cultured in various formats, including standard monolayer cultures in flasks or cell factories, or potentially adapted for growth in suspension culture using bbreactons for larger-scale production. Infection is typically initiated by adding a defined amount of virus inoculum, often quantified by Multiplicity of Infection (MOI), ie., the ratio of infectious virus particles to cells, to the cell culture and allowing infection and replication to proceed until significant viral replication or cytopathic effect (CPE) is observed, usually over several days.
[0118] Once maximal viral replication is achieved, the virus of the platform herein must be harvested and purified. Harvesting often involves collecting both the infected cells and the culture supernatant as poxviruses can remain cell-associated to varying degrees depending on the strain and cell type. Cell disruption methods, such as freeze-thaw cycles, sonication, or detergent lysis, may be employed to release intracellular virions. The crude viral lysate is then typically clarified by bw-speed centrifugation or filtration to remove large cellular debris. While this clarified lysate might suffice for many research applications or preliminary studies, purer preparations or larger scales necessitate concentration and purification steps. Concentration can be achieved by methods like ultracentrifugation or tangential flow filtration (TFF). Purification traditionally relies on centrifugation through sucrose density gradents or cesium chloride gradients to separate viral particles from cellular components based on buoyant density. More modem and scalable purification strategies may employ chromatographic methods, such as bn-exchange chromatography, affinity chromatography if applicable tags are present or using specific ligands, or size-exclushn chromatography. Throughout the production process, parameters are optimized to maximize viral yield and maintain infectivity. For large-scale or GMP production, robust process development and validation are required. The final purified virus preparation is typically resuspended in a suitable buffer containing stabilizers, e.g., glycerol, serum proteins, or specific buffer components, to maintain infectivity during storage, which is usually at low temperatures such as -80°C or in liquid nitrogen. Folbwing production,Docket No. 501.102. PCT
[0119] the virus stock must be accurately titered to determine the concentration of infectious virus particles. Standard methods include the plaque assay, which measures Plaque Foiming Units (PFU) per mL by counting visible zones of cell lysis (plaques) under an agarose overlay, orthe TCID50 assay (Tissue Culture Infectious Dose 50%), which determines the dilution of virus required to infect 50% of inoculated cell culture wells. Alternative or supplementary methods may include qPCR-based assays to determine the total number of viral genomes (genome copies / mL, which may differfrom infectious titer), or protein-based assays like ELISA to quantify viral antigen concentration.
[0120] Comprehensive characterization of the final recombinant virus stock of the platform herein is essential to confirm its identity, quality, and functionality. One key aspect is confirming antigen expression, ensuring the recombinant virus correctly expresses the intended heterologous polypeptide(s) at appropriate levels. This is typically verified using biochemical methods such as Western blotting with specific antibodies against the antigen or fusion partner, as shown in FIG.4, or immunofluorescence microscopy on infected cells, similar conceptually to FIG.3 but using antigen-specific reagents. ELISA on infected cell lysatescan also be employed. Flow cytometry can be used if the antigen is surface-expressed or if intracellular staining protocols are utilized. In some cases, functional assays relevant to the expressed protein, e.g., enzymatic activity, receptor binding, or hormone activity, might be performed.
[0121] Assessment of the replication kinetics of the virus the platform herein in vitro provides information on replication efficiency and the degree of attenuation, often compared to the parental attenuated strain and / orthe wild-type virus. This is commonly evaluated using multi-step growth curve analysis, where cells are infected at a low MOI and viral titers are measured at multiple time points over several days. Single-step growth curves, using a high MOI, can provide information about the duration of the replication cycle and burst size. Analysis may also include quantitative measurementor qualitative scoring of cytopathic effect (CPE) development over time, or measurement of plaque size, as highly attenuated viruses often produce smaller plaques than less attenuated or wild-type strains. Real-time monitoring of viral spread and CPE using live-cell imaging systems, e.g., Incucyte, can provide detailed kinetic data
[0122] Ensuring genetic stability is critical, especially for live replicating vectors, confirming that the inserted heterologous expression cassette® of the platform herein are stably maintained within the viral genome during replication and passage. Stability is typically assessed by serially passing the recombinant virus multiple times, e.g, 5, 10, or more passages, in permissive cells in vibo. The genetic integrity of the insert region and flanking sequences is then verified at different passage levels using PCR and DNA sequencing, either Sanger or WGS. Lessor rearrangement of the insert would indicate instability. Viral titer is also usually monitored across passages to ensure that replication competence is maintained. Genetic stability in wo may also be assessed by recovering virus from vaccinated animals after a period and sequencing the insert region.Docket No. 501.102. PCT
[0123] Safety and quality control measures are paramount for vaccination and immunocontraception. In vibo safety assessment of the platform herein may include evaluating cytotoxicity in relevant cell lines beyond simple CPE observation. In wo safety assessment the platform herein in the target species or relevant animal models involves monitoring for clinical signs of disease, adverse reactions at the injection site, effects on body weight as illustrated in FIG.7, and effects on temperature as shown in FIG.
[0124] 8. Potential vector shedding from relevant sites, e.g., oral, nasal, fecal, dermal, is evaluated using sensitive methods like qPCR, shown in FIG. 10. Bbdistri bution studies the platform herein may be conducted to determine where the vector disseminates and persists in the body. Histopathological examination of tissues at necropsy looks for inflammation or lesions, including evaluation of target organs like reproductive tissues. For production of the platform herein, particularly for veterinary biologies, rigorous quality control testing is implemented, often following established guidelines. This includes identity testing to confirm the virus of the platform herein is the correct recombinant construct, purity testing to measure and set limits for residual host cell DNAand proteins, potency testing often based on infectbus titer or an in vitro measure correlated with in wo efficacy, sterility testing for the absence of contaminating bacteria and fungi, mycoplasma testing, and adventitious agent testing to ensure absence of extraneous viruses using in vitro cell-based assays and potentially / n wiro assays in laboratory animals orembryonated eggs. For consistent production, a two-tiered seed lot system is often established, comprising a fully characterized Master Virus Seed (MVS) bank and derived Working Virus Seed (VWS) banks, from which production batches are generated.
[0125] Compositions and Formulations
[0126] The platform herein encompasses compositions comprising an effective amount of a recombinant poxvirus vector, as described in the preceding sections, formulated with a pharmaceutically acceptable or, more typically for the intended applications, a veterinarily acceptable carrier. These compositions are designed for administration to target animals to elicit the desired biological effect such as protective immunity against a pathogen like ASFV or induction of immunocontraception. The composition serves to stabilize the live recombinant poxvirus vector, facilitate its delivery to the subject and ensure its viability and potency until administration.
[0127] The veterinarily acceptable canier constitutes the bulk of the formulation and must be compatible with the live viral vector and nontoxic to the recipient animal at the administered dose. The nature of the carrier can vary widely depending on the intended route of administration and desired formulation properties For injectable formulations, the carrier is typically an aqueous, physiologically compatible buffer system, such as sterile saline (0.9% sodium chloride), phosphate-buffered saline (PBS), Tris-buffered saline (TBS), Ringer's solution, or cell culture medium like Minimum Essential Medium (MEM) or Hanks' Balanced Salt Solution (HBSS). These aqueous carriers ensure isotonicity and maintain a suitable pH range for viral stability. For other routes, such as oral or intranasal administration, different carriers may be employed, potentially including viscosity-enhancing agents or mucoadhesives to prolong contact time with mucosal surfaces.Docket No. 501.102. PCT
[0128] To enhance the stability of the live recombinant poxvirus of the platform herein, particularly during storage or transport, compositions may optionally include one or more stabilizers. Poxviruses are relatively stable, but stabilizers can help preserve infectivity, especially when subjected to fieeze-thaw cycles or lyophilization. Common stabilizers include proteins (e.g, bovine serum albumin (BSA), gelatin, lactalbumin hydrolysate), sugars (e.g, sucrose, lactose, trehalose, mannitol, sorbitol), polyols (e.g, glycerol), or certain polymers (e.g, polyvinylpyrrolidone (PVP)). The specific combination and concentration of stabilizers are optimized empirically for each vector and formulation type. For formulations intended for long-term storage or distribution in challenging environments, lyophilization (freeze-drying) may be employed. Lyophilized preparations contain the virus and appropriate cryoprotectants / lyoprotectants (often sugars or polyols) and are presented as a dry powder or cake that is reconstituted with a suitable sterile diluent (like sterile water or saline) immediately prior to administration. Lyophilized forms generally offer significantly improved shelf-life compared to liquid formulations, particularly at ambient temperatures.
[0129] Compositions may also contain other excipients. Preservatives (e.g, thimerosal, phenol, antibiotics like gentamicin) are sometimes included in multi-dose vial presentations to prevent microbial contamination after the vial is first punctured, although they are often omitted in single-dose vials or may be undesirable or unnecessary depending on the application and regulatory requirements. Buffering agents (e.g, phosphate, Tris, citrate) are used to maintain the optimal pH for viral stability. Tonicity agents (e.g, sodium chloride) ensure physiological compatibility for injectable or mucosal routes.
[0130] While poxviruses themselves possess inherent adjuvant properties due to their complex structure and ability to activate innate immune pathways, additional adjuvants are generally not required or included when using replication-competent attenuated poxvirus vectors. However, in certain situations, such as when using highly attenuated or replication-deficient poxvirus vectors (e.g, MVA, Avipox), or if a specific type of immune response needs to be strongly skewed (e.g, a robust TT1 response), the formulation might optionally include an external adjuvant Suitable adjuvants, if used, would need to be compatible with the live virus vector and could include aluminum salts (like alum, although less common with live viruses), oil-in-water emulsions (e.g, MF59-like, AS03-like), saponins (e.g, Quil-A or its derivatives like QS-21 ), Toll-like receptor (TLR) agonists (e.g, CpG oligonucleotides, poly l: C, monophosphoryl lipid A), or cytokine adjuvants, provided they do not unduly compromise vector viability or safety.
[0131] The compositions of the platform herein can be formulated for various routes of administration, selected based on the target species, the specific vector, logistical considerations for delivery (especially for wildlife), and the type of immune response desired. Parenteral routes include intramuscular (IM), subcutaneous (SC), or intradermal (ID) injection using standard needles and syringes or potentially needle-free injection devices. These routes are common for vaccinating domestic animals and allow for precise dose delivery. Mucosal administration targets immune inductive sites at mucosal surfaces and can be advantageous for inducing both systemic and mucosal immunity, which may be relevantfor pathogens entering via mucosal routes or for certainDocket No. 501.102. PCT
[0132] immunocontracepiive effects. Mucosal routes include oral administration, which is particularly attractive for wildlife applications where it can be incorporated into palatable baits (e.g., formulated into solid blocks, pellets, pastes, or liquids attractive to the target species like swine or canids). Oral delivery requires careful formulation to protect the virus from degradation in the gastrointestinal tract Intranasal administration via sprays, drops, or aerosols targets the nasal-associated lymphoid tissue. Other mucosal routes like ocular (eye drops), intrarectal, or intravaginal administration may be applicable in specific circumstances. Topical or dermal administration involves applying the virus preparation directly onto the skin, often following mild scarification (superficial abrasion) to allow viral entry into epidermal cells, a classical method used for Vaccinia virus vaccination. Direct application without scarification might be sufficient for some poxviruses or formulations. The route of administration can significantly influence the resulting immune response and potentially the shedding and transmission characteristics of the vector.
[0133] The dosage, or effective amount of the recombinant poxvirus of the platform herein administered will vary considerably depending on several factors, including the specific recombinant poxvirus construct (its identity, degree of attenuation, and inherent immunogenicity), the specific antigen (s) being expressed, the target animal species (its size, age, and immune status), the chosen route of administration, and the intended biological outcome (Ze., level of protection against ASFV challenge vs. duration and efficacy of immunocontraception). Generally, dosages for live replicating poxvirus vectors range broadly, for instance, from approximately 104to 109Plaque Foiming Units (PFU) or Tissue Culture Infectious Dose 50% (TCID50) per animal. Optimal dosages are deteimi ned empirically through dose-ranging studies in vitro and in wo. A key goal, particularly for wildlife and production animal applications, is to achieve the desired effect with a single administration. However, depending on the vector characteristics and the required level or duration of immunity or effect prime-boost regimens involving two or more administrations, potentially using the same vector or different vectors (heterologous prime-boost), might be considered in alternative embodiments. Compositions are typically packaged in appropriate containers, such as single-dose or multi-dose vials for injectable or reconstitutable foimulafions, or incorporated into specifically designed bait delivery units for oral administration to wildlife.
[0134] Methods of Use
[0135] The recombinant poxviruses and compositions of recombinant poxviruses of the platform herein provide versatile tools applicable to a range of methods aimed at improving animal health, managing animal populations, and addressing zoonotic disease risks. These methods generally involve administering an effective amount of a composition comprising the recombinant poxvirus vector to a target animal subject or population via an appropriate route.
[0136] One primary application is a method for inducing a protective immune response against a pathogen, such as African Swine Fever Virus (ASFV), in a susceptible host This involves administering a composition containing a recombinant poxvirus, such asDocket No. 501.102. PCT
[0137] an attenuated SWPV vector, engineered to express one or moie relevant ASFV antigens, to a swine subject The subject can be a domestic pig in an agricultural setting, aiming to prevent or reduce disease severity and economic losses, or it can be a feral or wild pig, aiming to reduce the viral load and transmission potential within reservoir populations, thereby indirectly protecting domestic herds. Administration, e.g., via injection or potentially oral baiting for feral populations, leads to vector infection, expression of the ASFV antigens, and the induction of a host immune response. This response ideally includes both humoral immunity, such as the production of neutralizing antibodies, and cellular immunity, including the activation of antigen-specific T lymphocytes (CD4+helperT cellsand CD8+cytotoxicT cells), conferring protection against subsequent natural infection or reducing the severity of disease upon challenge. The method may aim to prevent infection entirely, reduce clinical signs, decrease viral shedding, or lower mortality rates associated with ASFV.
[0138] Another significant application is a method for inducing immunocontraception in a target animal subject This method employs a recombinant poxvirus, selected for appropriate spedes-specificity (e.g, SWPV for swine, a suitable canid-specific poxvirus for dogs or coyotes, a feline-specific poxvirus for cats, etc.), engineered to express one or more immunocontraceptive antigens, such as a GnRH fusion protein or a ZP protein. Administration of an effective amount of this composition to the target animal induces an autoimmune response directed against the endogenous reproductive antigen. For example, induction of high-titer anti-GnRH antibodies, as demonstrated preliminarily in FIGS.5 and 12A, leads to neutralization of circulating GnRH, suppression of gonadotropin release, gonadal atrophy (potentially reflected in organ weight changes), and consequent infertility in both males and females. Similarly, anti-ZP antibodies induced by a ZP-expressing vector can block fertilization in females. This method provides a non-surgical, potentially long-lasting approach to sterilizing individual animals, applicable to companion animals (dogs, cats) as a low-cost alternative to spaying / neutering, orto manage wildlife or feral animals that can be captured and treated individually. The target animal can be any species for which a suitable species-specific poxvirus vector exists or can be developed and for which population control is desired, including but not limited to swine, canids, felids, rodents, lagomorphs, equids, cervids, camelids, and potentially others.
[0139] Furthermore, certain embodiments of the platform herein are specifically directed towards a method of controlling wild or feral animal populations using transmissible or self-disseminating immunocontraceptive vectors in the platform herein. This approach leverages the potential for certain live replicating poxvirus vectors, appropriately engineered, to be shed by initially vaccinated animals and subsequently transmitted horizontally to unvaccinated conspecifics within the population through natural social interactions and contact (as schematically depicted in FIG.1). For this method, a composition comprising a transmissible immunocontraceptive recombinant poxvirus (e.g, expressing a GnRH fusion protein) is administered, often via baits or targeted capture-and-release, to only a small fraction or subset of the target population (e.g, wild boar, feral dogs, coyotes, rabbits, rats). These initially infected individuals then act as mobile vector disseminators. Vector shedding, potentially occurring via oral, nasal,Docket No. 501.102. PCT
[0140] fecal, or dermal routes (informed by studies like those shown in FIG. 10, though specific transmissibility requires confirmation), leads to infection and induction of immunocontraception in contacted susceptible animals, propagating the sterilizing effect through the population over time without requiring direct human intervention for every individual. This "no-dose" strategy dramatically enhances the feasibility and cost-effectiveness of managing large, free-roaming, or inaccessible wildlife populations compared to methods requiring individual capture and treatment The success of this method depends on factors such as the efficiency of vector transmission, the stability of the vector intheenvironmentthe social structure and contact rates within the target population, and the duration of the induced infertility. Careful vector design and safety assessments are paramount for such applications.
[0141] The platform herein also encompasses a method for dual control of disease and population size, particularly relevant for wildlife reservoirs like feral swine. This method involves administering a single, dual-purpose recombinant poxvirus vector engineered to express both one or more antigens from a relevant pathogen (e.g, ASFV antigens) and one or more immunocontraceptive antigens (e.g., a GnRH fusion protein). Administration of such a vectorto feral swine aims to simultaneously reduce their capacity to maintain and transmit ASFV (protecting domestic agriculture) and limit their reproductive output (controlling ecological and agricultural damage). This integrated approach addresses interconnected problems with a single intervention tool.
[0142] Supporting these primary methods are methods for monitoring the effects of vector administration. These involve collecting biological samples from treated animals or populations over time. Samples can include serum or plasma for assessing systemic immune responses (e.g, antibody levels against vector antigens or expressed heterologous antigens using immunoassays like EUSA as shown in FIGS.5, 11, and 12; or virus neutralization assays), peripheral blood mononuclear cells (PBMCs)for evaluating cellular immune responses (e.g., T cell proliferation assays, ELISPOT assays detecting cytokine-secreting cells, flow cytometry analysis ofT cell phenotypes), or swabs (oral, nasal, rectal, dermal) or tissue samples for detecting vector presence, shedding, or persistence using molecular methods (e.g, qPCR as in FIG. 10) or virological methods (e.g, plaque assay for infectious virus as in FIG. 10, or virus isolation). Monitoring can also involve assessing physiological endpoints relevant to immunocontraception (e.g, measuring reproductive hormone levels, evaluating reproductive tract morphology via ultrasound or necropsy, observing breeding behavior, or tracking actual reproductive success rates in populations). For disease protection studies, monitoring involves assessing clinical signs, pathology, and survival rates following experimental or natural pathogen challenges. These monitoring methods aid in evaluating vector safety, immunogenicity, efficacy, shedding, and transmission during vector development and field application.
[0143] Vaccine PlatformDocket No. 501.102. PCT
[0144] The platform herein as the immunocontraceptive vaccine platform comprises: (1 ) a protein antigen comprising a GnRH-immunogenic protein fusion designed to trigger robust anti-GnRH immune responses, and (2) a viral vector for encapsulating a combined DNA construct for encoding the protein antigen. More particularly, the viral vector can be a rodent or porcine species-specific viral vector engineered to deliver the genetic encoding of the protein antigen directly into the target animal's cells; or not species specific for dogs (canines) and cats (felines).
[0145] Referring to FIG.1 B, the immunocontraceptive and blockade mechanisms are depicted in a left panel and a right panel, respectively. The left panel further illustrates the five-step immunocontraceptive mechanism. In step 1, the site of immunization occurs via oral ingestion or intramuscular injection. In step 2, the GnRH antibody is induced via B-cells. In step 3, there is immunological inhibition of GnRH. In step 4, there is inhibition of FSH and LH (the gonadotropins). In step 5, the reproductive organ is blockaded resulting in infertility. The right panel displays a detailed schematic of the reproductive hormone cascade, with the hypothalamus at the apex releasing GnRH, which stimulates the anterior pituitary to secrete FSH and LH (gonadotropins). These gonadotropins act on the gonads (testes and ovaries) to promote development of germ cells and synthesis of sex hormones (testosterone, estrogen, and progesterone). The right panel illustrates the blockade mechanism created by anti-GnRH antibodies (represented by orange dots), which interrupt GnRH signaling and prevent gonadotropin secretion, leading to infertility.
[0146] Referring to FIG.1 C, the vaccine is created by linking GnRH peptides to an immunogenic protein carrier via covalent linkages (i.e, a protein created through the joining of two or more genes that originally coded for separate proteins; or complex mutations (e.g., chromosomal translocation, tandem duplication, or retro-transposition) leading to a coding sequence containing parts of the coding sequences from two different genes) or non-covalent linkages (i.e., physical modification such that GnRH appends to the immunogenic protein carrier via stabilizing interactions). The combined DN which encodes both the protein carrier and GnRH polypeptide sequences (e.g., SEQ I D NOs 1-11), is then encapsulated within a viral vector, which is administered to the animal. Upon infection, the viral vector delivers this genetic material to animal cells, where the GnRH-fusion protein is produced, triggering both innate and adaptive immune responses. The GnRH-protein carrier fusion, which is the protein antigen, can be one of, but not limited to, SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO 9, SEQ ID NO: 10, or SEQ ID NO: 11. The combination of these components creates a functional vaccine that can be administered orally or by intramuscular injection, with cellular uptake and immune activation occurring within 3 to 10 days post-vaccination.
[0147] Protein Antigen Composition and Design
[0148] The protein antigen may be a chimeric construct in which gonadotropin-releasing hormone (GnRH) peptide sequences are fused to an immunogenic bacterial protein carrier. The protein carrier serves dual functions: providing a scaffold for presenting multipleDocket No. 501.102. PCT
[0149] copies of GnRH in a surface-accessible configuration and contributes its own immunogenic properties to enhance the overall antibody response against the antigen. FIG. 14 illustrates the immunogenic bacterial proteins employed in the platform (MBO, STF2, and CRM197). Other bacterial proteins [Tetanus Toxoid (TT), which is derived from Clostridium tetani; Cholera Toxin Subunit B (CTB), which is produced by Vibrio cholerae; Protein D from Haemophilus influenza, which is a highly conserved surface lipoprotein; and Outer Membrane Protein Complex (OMPC) sourced from Neisseria meningitidis, wherein OMPC is a large, particulate protein complex; and heat-Labile Enterotoxin B Subunit (LTB) derived from Escherichia coli), in combination with the GnRH peptides, can be employed in a platform for a vaccine. The immunogenic bacterial proteins, such as, but not limited to MBO, STF2, CRM197, TT, CTB, Protein D, OMPC, and LTB ), can be linked to GnRH peptides (i.e., polypeptide linkage) to yield protein antigens that can be delivered via species-specific or species non-specific vector, wherein the GnRH peptides are in chimeric or fusion form. With respect to the polypeptide linkage, the immunogenic bacterial proteins can have: (1 ) units of GnRH interspersed within the bacterial immunogenic bacterial protein (chimeric proteins); or (2) units of GnRH appended to the bacterial immunogenic bacterial protein (fusion proteins). The result of these designed constructs is an increase in the antigenicity vaccine in the target host culminating in higher titers of anti-GnRH antibodies.
[0150] Maltose-Binding Protein (MBP) is a bacterial enzyme that functions as the protein carrier in multiple vaccine candidates. MBP possesses inherent structural stability, known intrinsic adjuvant properties that enhance immune responses, and experimentally validated permissive sites for epitope insertion. The two domains of MBP are connected by flexible linkers, allowing for multi-site epitope grafting that presents GnRH peptides in flexible, solvent-exposed orientations optimal for immune recognition.
[0151] Flagellin (STF2) is a bacterial structural protein derived from Salmonella. Flagellin is renowned for its strong immunogenic properties and functions as a naturally occurring adjuvant by engaging pattern recognition receptors on immune cells. When fused to GnRH peptides, flagellin provides both a stable protein scaffold and a built-in immune stimulant, enhancing the magnitude and durability of anti-GnRH antibody responses.
[0152] CRM 197 is an inactive variant of diphtheria toxin from Corynebacterium diphtheriae, selected as a carrier protein because of its well-characterized structure, thermal stability, clearly defined B-cell epitopes in non-structured surface regions, and extensive history of safe use in approved human fusion vaccines. FIG.3 shows that MBP and flagellin are used as carriers for GnRH fusion proteins (where multiple tandem GnRH copies are fused to the protein), while CRM197 and MBP variants are used for GnRH chimeric proteins (where GnRH peptides replace linear B-cell epitopes of the carrier protein via epitope grafting).
[0153] The platform comprises vaccine candidates (TF1 through TF14), each incorporating different protein scaffolds and GnRH presentation geometries to optimize immune response, while maintaining structural integrity and manufacturing feasibility.
[0154] TF1 (MBP-12xGnRH) comprises Maltose-Binding Protein carrying twelve tandem copies of GnRH arranged as a fusion proteinDocket No. 501.102. PCT
[0155] TF2 (GnRH12x-MBP) reverses the orientation, with GnRH copies at the N-terminal side of MBP, allowing investigation of how antigen orientation affects immunogenicity.
[0156] TF3 (MBP-GnRH12xmut) comprises mutations in the GnRH sequence to explore sequence variants that may enhance immunogenicity or reduce potential off-target immune reactions.
[0157] TF4 (MBP-intemal GnRH12x) comprises positions of GnRH insertions within internal loop regions of MBP rather than at the termini, testing whether internal presentation affects antibody targeting and antigen processing.
[0158] TF5 (MBPmut-GnRHI 2x) comprises mutations in the MBP carrier protein itself, which may influence the protein's immunogenicity or intrinsic adjuvant properties.
[0159] TF6, designated TCG13 in FIG.3, comprises the CRM197 scaffold with thirteen GnRH peptides inserted via epitope grafting into non-structured surface regions of the protein (i.e., interspersal of GnRH peptides).
[0160] TF7 (STF2-12xGnRH) comprises flagellin as the carrier protein, with twelve GnRH copies fused at or within the structural protein, combining the strong immunogenicity of flagellin with GnRH presentation.
[0161] TF8 (VHH-GnRH-206) employs a camelid-derived single-domain antibody (nanobody or VHH) directed against GnRH as the carrier, creating an antigen structure where an anti-GnRH antibody itself serves as the platform for GnRH presentation.
[0162] TF9 (MGXX, eg., MG09L) represents a variant carrier system based on MBP with alternative insertion patterns or additional design modifications to optimize immune response. Species of TF9 includes: MG09, MG09L, MG10, and MG10L.
[0163] TF10 comprises antigen-encoded sequences within the poxvirus vector, such as a promoter (e.g., mH5); and the coding sequences for the GnRH fusion proteins of STF2-GnRH.
[0164] TF11 comprises antigen-encoding sequences within the poxvirus vector, such as a promoter (e. g., mH5); a signal peptide (e.g, CD33 sp); and the coding sequences for the GnRH fusion proteins of MBP-GnRH. In this embodiment the CD33 signal peptide leads to the secretion of the GnRH fusion protein antigen which contributes to a stronger immune response.
[0165] TF12 (VHH-GnRH-206) comprises encoded VHH-GnRH-206 protein, but does not encode for STF2-GnRH or MBP-GnRH.
[0166] TF13 (AAV9-VHH(1 w13 vg / kfg)) comprises encoded AAV9-VHH(1 w13 vg / kfg) protein, but does not encode for STF2-GnRH or MBP-GnRH.
[0167] TF14 (OVA-GnRH) comprises Ovalbumin-fused Gonadotropin-Releasing HormoneDocket No. 501.102. PCT
[0168] Comparative efficacy data showing the impact of each candidate on testis weight reduction, testosterone suppression, and anti-GnRH antibody generation are disclosed herein.
[0169] Structure-Guided Computational Design
[0170] The design of MBP-based antigen constructs employed rigorous computational protein structure modeling to ensure that GnRH insertions do not disrupt the stability, function, or immunogenicity of the carrier protein scaffold. The design process began with secondary structure prediction using DSSP (Define Secondary Structure of Proteins) to identify regions of the protein localized to the surface and predicted to be flexible or unstructured. Nine candidate insertion sites were initially identified within loop and turn regions, selected for their surface accessibility and their distance from the maltose-binding active site. The high-resolution crystal structure of MBP (PDB code 1 ANF, X-ray crystallography structure of hob-MBP bound to maltose with residues 27-370 resolved) served as the template for structural modeling.
[0171] Comparative structure modeling was performed using MODELLER, generating atomic-resolution models of MBP-GnRH constructs incorporating one or more GnRH sequences at each candidate insertion site. All models indicated that GnRH insertions remained surface-exposed and extended away from the MBP scaffold, positioning the peptide optimally for immune recognition without disrupting the protein core. Artificial intelligence-based structure prediction using ColabFold (an implementation of AlphaFold2) independently validated the designs by predicting the full three-dimensional structures of MBP-GnRH chimeras. Predicted structures exhibited root-mean-square deviation (RMSD) values less than 1 Angstrom relative to the original X-ray structure, confirming that GnRH insertions did not alter the MBP protein fold and that the chimeric proteins maintained structural and functional integrity.
[0172] Molecular dynamics (MD) simulations were conducted using AMBER molecular dynamics software with the ff19SB force field and TIP3P water model. The MBP structure was solvated in a truncated octahedral water box with a 12 Angstrom buffer, neutralized with Na+ and Cl- counterions, and subjected to multi-stage energy minimization and equilibration protocols.
[0173] Production runs extended for 1 microsecond under NPT conditions (1 atm, 300 K) with a 2 femtosecond timestep. Trajectory analysis assessed protein stability using root-mean-square deviation (RMSD), root-mean-square fluctuation (RMSF), and radius of gyration (Rg) calculations. Baseline MBP wild-type stability demonstrated an average RMSD of 3.3 Angstroms with no residue exceeding RMSF of 4 Angstroms, establishing a stability benchmark. MD simulations of MBP-GnRH constructs revealed that GnRH insertions at selected positions did not disrupt the overall protein stability, with constructs maintaining average RMSD values below 5 Angstroms and increased RMSF values localized only to the immediate vicinity of the insertion sites, confirming that GnRH peptides remained flexible and surface-exposed while the MBP scaffold remained structurally intactDocket No. 501.102. PCT
[0174] Based on MD results and literature validation of specific insertion sites, the following constructs were selected for experimental validation: Construct 1 (positions 32, 74, 101, 122, 166, 185, 240, 253, 317, single insertion each); Construct 2 (positions 32, 122, 166.253.317, single insertion each); Constructs (positions 166, 317, double insertion); and Construct4 (positions 122, 166, 185, 240.317, double insertion). In each case, construct variants incorporating SGG (Ser-Gly-Gly) flexible linker sequences between insertion sites and GnRH peptides were also designed to further optimize epitope flexibility and accessibility.
[0175] For split-protein applications, the scaffold was subjected to computational fragmentation analysis to identify dissection points that minimize the exposure of the hydrophobic core while maintaining the integrity of secondary structure elements. Candidate split sites were prioritized at surface-exposed loops identified by DSSP, specifically those where the cleavage would not lead to irreversible misfolding of the individual N- and C-terminal fragments.
[0176] Molecular dynamics (MD) simulations were employed to calculate the binding free energy (ΔGbind) of the reassembled complex and the solvent-accessible surface area (SASA) of the newly formed interfaces. Successful split-site candidates were defined by their ability to maintain a native-like fold in the assembled state— quantified by an inter-domain RMSD <2.5 A— while demonstrating high local flexibility at the split termini to facilitate sterically unhindered fragment association.
[0177] While Ser-Gly-Gly (SGG) linkers provide flexibility, other applications may require rigid spacers to prevent the peptide from ''collapsing" onto the scaffold or cleavable motifs for controlled release. To optimize the spatial presentation of the inserted orfused sequences, a library of linker architectures was evaluated based on the required effective molarity and orientation of the guest peptide. These library linkers include, but not limited to: flexible tetra-glycine-serine motifs, utilized to maximize the conformational search space of the epitope, ensuring high accessibility for BCR / TCR recognition; rigid alpha-helical spacers, such as (EAAAK)-containing motifs, utilized to maintain a fixed distance between the scaffold and the peptide, thereby preventing unfavorable steric interactions with the carrier surface; and cleavable linkers, such a protease-sensitive motifs (Val-Cit or cathepsin-B cleavage sites) that are not buried in a scaffold-peptide interface, but accessible to solvents.
[0178] Viral Vector
[0179] The platform herein can use species-specific viral vectors for delivery. The vectors are engineered, attenuated poxviruses selected from, for example, the genus Orthopoxvirus, each adapted for replication only within its target host species. This speciesspecificity ensures that the vaccine replicates exclusively in the intended pest species and not in non-target organisms, thereby achieving long term contraception through persistent release of GnRH suppressing nanobodies from long lived muscle cells.
[0180] For rodents, the platform herein employs Volepox Virus, a poxvirus naturally associated with voles and other small rodents. As depicted in FIG. 17, the rodent-specific vector employed in this platform is an attenuated Volepox Virus with genes deleted from itsDocket No. 501.102. PCT
[0181] genome, wherein the deleted genes can encompass Genes 1, 2, 3, 4, 5, 6, 7, 8, 9, 10, 11, 12, 13, 14, 15, 16, 17, 18, 19, and 20 deleted from the attenuated Volepox Virus.
[0182] Gene 1 is an ifh resistance protein CDS (locus tag B1079 _gp033) spanning from a minimum of 19643 to a maximum of 19897 with a length of 255, a reverse direction, and a length ^vith gaps) of 255. Gene 2 is a serpin CDS (locus tag B1079_jgp032) spanning from a minimum of 18473 to a maximum of 19591 with a length of 1119, a reverse direction, and a length (with gaps) of 1119. Gene 3 is an ankyrin / nfkb inhibitor CDS (locus tag B1079_gp031) spanning from a minimum of 17463 to a maximum of 18320 with a length of 858, a reverse direction, and a length (with gaps) of 858. Gene 4 is an nfkb inhibitor CDS (locus teg B1079_gp030) spanning from a minimum of 16701 to a maximum of 17357 with a length of 657, a reverse direction, and a length (with gaps) of 657. Gene 5 is an ankyrin CDS (locus tag B1079_jgp029) spanning tram a minimum of 15320 to a maximum of 16660 with a length of 1341, a reverse direction, and a length (with gaps) of 1341. Gene 6 is a putative tir signaling inhibitor CDS (locus tag B1079_gp028) spanning from a minimum of 14684 to a maximum of 15271 with a length of 588, a reverse direction, and a length (with gaps) of 588. Gene 7 is an anti-apoptotic bcl-2-like protein CDS (locus tag B1079_gp027) spanning from a minimum of 14236 to a maximum of 14589 with a length of 354, a reverse direction, and a length (with gaps) of 354. Gene 8 is a putative tir signaling inhibitor CDS (locus tag B1079__gp026) spanning from a minimum of 13566 to a maximum of 14192 with a length of 627, a reverse direction, and a length (with gaps) of 627. Gene 9 is a poz / btb kelch domain protein CDS (locus tag B1079_gp025) spanning from a minimum of 11964 to a maximum of 13493 with a length of 1530, a reverse direction, and a length (with gaps) of 1530. Gene 10 is a complement binding CDS (locus tag B1079_gp024) spanning from a minimum of 11122 to a maximum of 11901 with a length of 780, a reverse direction, and a length (with gaps) of 780. Gene 11 is an il-1 receptor antagonist CDS (locus tag B1079_gp023) spanning from a minimum of 10092 to a maximum of 11048 rath a length of 957, a reverse direction, and a length (with gaps) of 957. Gene 12 is a protein CDS (locus tag B1079_gp022) spanning from a minimum of 9420 to a maximum of 10025 with a length of 606, a reverse direction, and a length (with gaps) of 606. Gene 13 is a bcl-2-like protein CDS (locus tag B1079_gp021) spanning from a minimum of 8835 to a maximum of 9302 with a length of 468, a reverse direction, and a length (with gaps) of 468. Gene 14 is a type 1 inhibitor CDS (locus tag B1079„gp020) spanning from a minimum of 8148 to a maximum of 8597 with a length of 450, a reverse direction, and a length (with gaps) of 450. Gene 15 is a protein CDS (locus tag B1079_gp019) spanning from a minimum of 7548 to a maximum of 8102 with a length of 555, a reverse direction, and a length (with gaps) of 555. Gene 16 is an ankyrin CDS (locus tag B1079_gp018) spanning from a minimum of 5604 to a maximum of 7499 with a length of 1896, a reverse direction, and a length (with gaps) of 1896. Gene 17 is a protein CDS (locus tag B1079_gp017) spanning from a minimum of 5310 to a maximum of 5498 with a length of 189, a reverse direction, and a length (with gaps) of 189. Gene 18 is an ankyrin / host range CDS (locus tag B1079_gp016) spanning from a minimum of 3362 to a maximum of 5203 with a length of 1842, a reverse direction, and a length (with gaps) of 1842. Gene 19 is a soluble il-18 binding protein CDS (locus tag B1079_gp015) spanning from a minimum of 1675 to a maximum of 2007 with a length of 333, aDocket No. 501.102. PCT
[0183] reverse direction, and a length (with gaps) of 333. Gene 20 is a zinc finger-like protein CDS (locus tag Bl 079_gp014) spanning from a minimum of 833 to a maximum of 1585 with a length of 753, a forward direction, and a length (with gaps) of 753.
[0184] This engineered vector in FIG. 17 has been further modified to express green fluorescent protein (GFP) under the control of a poxvirus promoter, enabling visual confirmation that the virus replicates only in rodent cells. In vitro testing across cell lines from multiple species (rodent, avian, porcine, and feline) demonstrated that the rodent-specific Volepox vector with GFP insert produced fluorescence exclusively in rodent cell lines, confirming species-specificity at the cellular level. The GFP was removed using CRE / LOX in production vaccines, i.e., GFP is only used for testing of efficacy and species specificity.
[0185] For wild boars and pigs, the platform herein employs Swinepox Virus, a poxvirus naturally associated with swine. As shown in FIG. 18, this virus has been attenuated through selection and engineering to reduce virulence while maintaining replication capacity in porcine cells. Like the rodent vector, the porcine-specific Swinepox Virus has been engineered to express GFP, allowing visual confirmation of species-specific replication. In vitro evaluation across rodent, avian, porcine, and feline cell lines demonstrated that the Swinepox vector with GFP insert produced fluorescence exclusively in porcine cell lines, confirming species-specificity at the cellular level, the GFP was removed using CRE / LOX in production vaccines, i.e., GFP is only used for testing of efficacy and species specificity.
[0186] The platform herein can alternatively be non-specific viral vectors for delivery, engineered, for example, canary pox infecting canine muscle cells (MyoK9). Myoblasts and myotubes derived from MyoK9 canine muscle cells were infected with an ALVAC vector (replication-defective canarypox virus vector) expressing GFP across mock, 1.0 MOI, and 0.1 MOI trials, with both cell types supporting robust transgene expression, as depicted in FIG.25. Interestingly, while the GFP intensity in myoblasts remained similar between the 1.0 and 0.1 MOI trials, the intensity in myotubes was substantially different across the two dosages. This divergence may indicate that the smaller, mononucleated myoblasts reach a transcriptional or translational "saturation point" even at low multiplicities of infection, where the cellular machinery is fully occupied and additional viral templates (1.0 MOI) do not yield higher protein output Conversely, the massive, multinucleated myotubes possess a significantly larger cytoplasmic volume and a higher "expression ceiling." At 0.1 MOI, the vector likely engages only a fraction of the available nuclei or results in a more diluted protein signal; however, increasing the dose to 1.0 MOI allows for a clear, dose-dependent escalation in intensity as more viral particles exploit the metabolic resources of the mature muscle fiber. The GFP was removed using CRE / LOX in production vaccines.
[0187] The platform herein can alternatively be non-specific viral vectors for delivery, engineered, for example, canary pox infecting avian (DF-1 ) muscle cells and MyoK9 muscle cells. A variety of species of promoters were investigated (MH5, H6, pSEL, pO2L_pA12L, pE3L_pF17R, p11, p7.5, p132, p132-11, and p132-MH5 in DF-1 muscle cells and MyoK9 muscle cell) for optimalDocket No. 501.102. PCT
[0188] expression of GFP, as depicted in FIG.26. MH5 was deteimined to be the optimal promoter for expression of GFP. The GFP was removed using CRE / LOX in production vaccines.
[0189] The longitudinal screening of ALVAC-GFP at a low infectious dose (50 PFU) across a diverse panel of cell lines including DF-1 (avian fibroblasts), U-2 OS (human osteosarcoma), PK-15 (porcine kidney), Vero (African green monkey kidney), MDCK (canine kidney), A549 (human lung carcinoma), F81 (feline kidney), and 2937717 (human embryonic kidney), as depicted in FIG. 19. At seven days post-infection, the fluorescence levels in the ALVAC-treated groups appeared nearly indistinguishable from the uninfected controls. The "feint intensities" observed across all samples— including those that were uninfected— are likely a result of background autofluorescence captured during the extended image exposure times required forthese trials. These results indicate substantially different fluorescent behavior than MH5 promoter-GFP fluorescence in MyoK9 and DF-1 cells from FIG.26. While those cells in FIG.27 allow for immediate transgene expression, the lack of visible green "plaques" or expanding infection clusters in the mammalian lines over a full week strongly suggests that ALVAC is an abortive vector in these hosts that can deliver a genetic payload for short-term protein production.
[0190] Poxvirus vectors possess multiple properties that make them suitable delivery platforms for an immunocontraceptive vaccine. Poxviruses have a long history of safe use in human vaccines, establishing regulatory precedent and public health familiarity. Poxviruses are characterized by strong immunogenicity, reliably inducing robust cellular and humoral immune responses. Poxviruses maintain stable expression of heterologous genes delivered to target cells, ensuring sustained production of the GnRH-fusion antigen throughout the infection. Poxviruses exhibit thermostability, retaining infectivity under field conditions at elevated temperatures that would inactivate other viral vectors, enabling oral vaccine delivery baited on feed or in drinking water. Selected poxviruses can be administered orally, allowing non-invasive vaccine delivery without the need for individual animal capture, restraint or injection, a critical advantage for landscape-scale pest population management
[0191] Gene Therapy Approach
[0192] In addition to the poxvirus-based immunocontraceptive approach, the platform can further encompass an alternative strategy employing gene therapy to achieve lasting contraception. The gene therapy approach utilizes adeno-associated virus (AAV) vectors, which integrate their genetic cargo into the host cell genome, enabling permanent production of anti-GnRH antibodies. As depicted in FIG.23, the AAV9-GnRH nanobody (nAb) construct encodes a variable domain of a heavy-chain-only antibody (VHH) directed specifically against GnRH. This construct comprises: CBA (a chicken promoter containing the CMV early enhancerfor constitutive expression), SSP (a secretory signal peptide for protein targeting), Kozak (a Kozak translation initiation sequence to facilitate efficient translation), VHH (the variable domain of a heavy-chain-only antibody against GnRH, approximately 15 kilodaltons), WPRE (a regulatory element that enhances virus stability in packaging cells), and pA (a polyadenylation signal for transcription termination). Upon intramuscular injection, the AAV vector infects muscle cells, and theDocket No. 501.102. PCT
[0193] vector genome integrates into the host chromosome, establishing permanent constitutive production of the anti-GnRH nanobody. The nanobody is secreted from muscle cells and binds and neutralizes GnRH, which may lead to contraception..
[0194] Mechanism of Action
[0195] The vaccine achieves contraception through a well-characterized biological cascade, illustrated in FIG.2A, which depicts the seven sequential steps (labeled 110 through 710) of the vaccine mechanism. Step 110 shows the combination of a gene encoding a reproductive hormone (in this case GnRH) with DNA from bacteria (the immunogenic protein carrier). Step 210 depicts insertion of this combined DNA into a weakened vims used as a vaccine vehicle. Step 310 shows administration of the vaccine via injection or oral delivery. Step 410 illustrates cellular uptake of the vaccine, which occurs within 3 to 10 days postvaccination. Step 510 depicts production of the protein antigen (the GnRH-immunogenic protein fusion) within the infected cell and presentation thereof on the cell surface. Step 610 shows immune system recognition of the antigen as foreign, with B-cells generating anti-GnRH antibodies. Step 710 demonstrates how the anti-GnRH antibodies, which is attributed to resemblance of the native reproductive hormone, neutralization of native GnRH and blockage of reproductive hormone signaling, thereby leading to contraception and long-term sterilization.
[0196] FIG.2B illustrates an alternative gene therapy mechanism (steps 11 through 17). I n step 11, a gene is encoding a tiny antibody (nanobody) to a canine reproductive hormone being engineered into a weak virus, as represented by a DNA construct with the nanobody gene entering a virus particle. In step 12, this viral vaccine is injected into muscle cells (e.g., a syringe delivering the vaccine to muscle tissue). In step 13, cellular uptake of the vaccine in muscle cells occurs 3 to 10 days. In step 14, there is viral integration of the nanobody gene into the muscle cell chromosome, triggering continuous antibody production. In step 15, antibodies are: entering the bloodstream and traveling to reproductive tissues. In step 16, antibodies are attaching to native reproductive hormones, thereby preventing their interaction with receptors (i.e, preventing binding of antibodies to receptor cells). In step 17, there is blockage of receptor binding, which breaks the hormonal pathways required for reproduction (e.g, hypothalamus-pituitary-gonad axis with the GnRH-mediated signal disrupted, preventing FSH and LH secretion and ultimately leading to contraception). This gene therapy approach differs from the immunocontraceptive vaccine in that antibody production is constitutive and permanent
[0197] Antibody Persistence and Durability
[0198] A significant advantage of the poxvirus-based vaccine platform is the durability of anti-GnRH antibody responses. FIG.20 compares the persistence of antibody responses between viral vector-based vaccines and non-replicating protein-based vaccines, referencing published data from Amanna et al. (New England Journal of Medicine 357.19, 2007). Viral vector-based vaccines, such as the poxvirus platform disclosed herein, elicit antiviral antibody responses that remain stable and elevated forDocket No. 501.102. PCT
[0199] prolonged periods, maintaining functionality over years. In contrast antibody responses against protein-based vaccine antigens wane more rapidly, with half-lives measured in years rather than the multi-year persistence of viral vector-induced responses This fundamental difference in antibody durability makes the poxvirus platform substantially more attractive for a single-dose contraceptive application, as the sustained anti-GnRH antibody titers maintain reproductive suppression without requiring booster vaccinations.
[0200] The immunocontraceptive vaccine platform provided multiple technical advantages over existing vertebrate pest control methods Single-dose efficacy, unlike existing contraceptive vaccines that require repeated intramuscular injections over months or years, of the platform achieves long-term infertility with a single administration. Cellular uptake of the vaccine and initiation of anti-GnRH antibody production occur within 3 to 10 days post-vaccination, rapidly establishing contraceptive immunity. This single-dose design eliminates the need for repeated animal capture, handling, and injection, dramatically reducing logistical complexity and cost of large-scale pest population management
[0201] Species specificity is a safety feature and a major advancement over chemical and non-specific biological control methods. As demonstrated in FIG. 17 and FIG. 18, the engineered poxvirus vectors replicated only within their target host species, confirmed by in vitro testing across cell lines from multiple species. This ensures that vaccine virus does notspread to non-target wildlife, and that only target pest species mount anti-GnRH immune responses. This level of species-specificity cannot be achieved with rodenticides or other chemical control agents, which are indiscriminate and affect all exposed organisms. Species-specific control significantly reduces regulatory burden and allows sustainable pest management that preserves non-target biodiversity and ecosystem integrity. Additionally, porcine specific promoters, like Porcine Rosa26 Promoter (p R26) can be used to further limit expression of the transgene in off-target species. Additionally, sites for microRNA specific to non-pordne species, like fef-7 (specific to humans), can be encoded into the 3’ UTR of the transgene. If the virus accidentally jumps species, the human ubiquitous miRNA will bind to the target microRNA site and deactivate the mRNA for the transgene, preventing the contraceptive protein from ever being translated.
[0202] Oral delivery capability of the platform addresses a critical operational barrier of existing contraceptive vaccines. Selected poxvirus vectors, particularly Swinepox Virus, maintain sufficient thermostability and infectivity under field conditions to permit oral administration via baited feed or water. This eliminates the requirement for individual animal capture, restraint and injection, enabling landscape-scale vaccine distribution without intensive husbandry infrastructure. Oral delivery dramatically reduces animal stress and handling injuries, improves welfare, and enables distribution to free-ranging or semi-wild pest populations in remote or difficult-to-access locations.Docket No. 501.102. PCT
[0203] Strong and durable immune responses may be atributed to the combination of multiple features of the protein antigen and vector. The protein antigens are multivalent, presenting 12 or more copies of GnRH per antigen molecule, amplifying the antigenic signal and eliciting higher-titer antibody responses than would be achieved with a single GnRH peptide. The protein canier (MBP, flagellin, CRM197, or other antigenic proteins) contributes its own immunogenic properties, further enhancing immune activation. The poxvirus vector is naturally immunoslimulatory and replicates within target cells for limited periods, extending exposure to the antigen and promoting sustained immune activation. As shown in FIG. 20, antiviral antibody responses elicited by poxvirus vectors of the platform remain remarkably stable and elevated, in contrast to protein-based vaccines where antibody titers wane more rapidly (i.e, protein-based vaccines do not remain stable and elevated).
[0204] Elimination of environmental hazards represents a transformative advantage over chemical rodenticide-based control. Chemical rodenticides present significant secondary poisoning risk, bioaccumulation in predators, ecosystem disruption, and regulatory scrutiny. The immunocontraceptive vaccine approach generates no persistent chemical residues, does not bioaccumulate, and does not poison non-target predators. The vaccine itself is biodegradable (the viral vector is cleared within weeks) and leaves no environmental persistence. Off-target organisms are not exposed because the vaccine replicates only in target species and does not cause clinical disease requiring systemic treatment or environmental contamination.
[0205] Regulatory compatibility is enhanced by the platform's pedigree and safely profile. The poxvirus vector platform has prior use in human vaccines, including smallpox vaccine and recently approved vaccinia-based vaccines, providing regulatory precedent and familiarity to health and agriculture regulatory bodies. The antigens are recombinant versions of naturally occurring proteins (bacterial enzymes and structural proteins) or minor variations thereof, without creation of novel, non-natural epitopes that might raise safely concerns. The platform sidesteps restrictions on lethal control methods and avoids the environmental and secondary poisoning issues that have prompted legislative action such as California AB 1788, positioning the vaccine favorably for regulatory approval and public acceptance.
[0206] VHH nanobodies directed against GnRH and FSH
[0207] The platform herein may comprise: anti-GnRH VHH and anti-FSHp, which are each structurally distinct from VHH-GnRH-206 and AAV9-VHH. The nanobodies of VHH-GnRH-206 and AAV9-VHH (an AAV expressing VHH-GnRH-206), which did not show any effect in targeting either the GnRH hormone or the FSH, motivated the generation and screening of the new, improved VHHs disclosed herein. The anti-GnRH and anti-FSH VHHs structurally distinct from VHH-GnRH-206 and AAV9-VHH can encompass VHH libraries, wherein the VHH libraries comprise nanobodies that target either the GnRH hormone or the FSH, wherein the nanobodies in the VHH libraries are structurally distinct from VHH-GnRH-206 and AAV9-VHH. (See FIG. 9.) There was screening of 94 individual colonies, which depict; for example, in FIG. 9, an enrichment readout for screening, with GnRH panned successively against GnRH-HisTag (Pannings 1-2) and OVA-GnRH fusion (Pannings 3-6), and FSH panned againstDocket No. 501.102. PCT
[0208] human FSHP-HisTag (Pannings 1-4). For example, a phage ELISA against GnRH-HisTag ata 1:10 dilution comparing day-0 (dO) and day-30 (d30) phage pools, illustrated round-over-round enrichment of GnRH-binding clones in the panning output (See FIG. 5).
[0209] The anti-FSHp VHH nanobodies can selectively bind FSHp relative to control proteins. In particular, the anti-FSHp VHHs are polypeptides selected from: VHH-FSHB-B4 (SEQ ID NO: 12); VHH-FSHB-B7 (SEQ ID NO: 13); VHH-FSHB-C7 (SEQ ID NO: 14); VHH-FSHB-Custer 12 (SEQ ID NO: 15); VHH-FSHB-Cluster20 (SEQ ID NO: 16); VHH-FSHB-D3 (SEQ ID NO: 17); VHH-FSHB-D7 (SEQ ID NO: 18); VHH-FSHB-D8 (SEQ ID NO: 19); VHH-FSHB-D9 (SEQ ID NO: 20); VHH-FSHB-D10 (SEQ ID NO: 21); VHH-FSHB-E7 (SEQ ID NO: 22); VHH-FSHB-E11 (SEQ ID NO: 23); VHH-FSHB-F3 (SEQ ID NO: 24); VHH-FSHB-F7 (SEQ ID NO: 25); VHH-FSHB-F11 (SEQ ID NO: 26); VHH-FSHB-G5 (SEQ ID NO: 27); VHH-FSHB-G7 (SEQ ID NO: 28); and VHH-FSHB-H2 (SEQ ID NO: 29).
[0210] Polypeptides selected from SEQ ID NO: 12, SEQ ID NO: 13, SEQ ID NO: 14, SEQ ID NO: 15, SEQ ID NO: 16, SEQ ID NO: 17, SEQ ID NO: 18, SEQ ID NO: 19, SEQ ID NO: 20, SEQ ID NO: 21, SEQ ID NO: 22, SEQ ID NO: 23, SEQ ID NO: 24, SEQ ID NO: 25, SEQ ID NO: 26, SEQ ID NO: 27, SEQ ID NO: 28, and SEQ ID NO: 29 are encoded by the nucleotides selected from SEQ ID NO: 41, SEQ ID NO: 42, SEQ ID NO: 43, SEQ ID NO: 44, SEQ ID NO: 45, SEQ ID NO: 46, SEQ ID NO: 47, SEQ ID NO: 48, SEQ ID NO: 49, SEQ ID NO: 50, SEQ ID NO: 51, SEQ ID NO: 52, SEQ ID NO: 53, SEQ ID NO: 54, SEQ ID NO: 55, SEQ ID NO: 56, SEQ ID NO: 57, and SEQ ID NO: 58, respectively.
[0211] In further embodiments, the anti-FSHp VHH nanobodies comprise the CDR1, CDR2, and CDR3 sequences of any of the foregoing VHHs, optionally grafted onto an alternative VHH framework. In further embodiments, the disclosure provides anti-FSHp VHH nanobodies sharing at least 80% at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% sequence identity to any of the foregoing sequences, while retaining selective binding to FSH.
[0212] The anti-GnRH VHH nanobodies can selectively bind GnRH-fused antigens relative to unfused controls. In particular, the anti-GnRH VHHs are polypeptides selected from: VHH-GnRH-B3 (SEQ ID NO: 30); VHH-GnRH-B5 (SEQ ID NO: 31); VHH-GnRH-B7 (SEQ ID NO: 32); VHH-GnRH-C5 (SEQ ID NO: 33); VHH-GnRH-C9 (SEQ ID NO: 34); VHH-GnRH-Cluster53 (SEQ ID NO: 35); VHH-GnRH-D3 (SEQ ID NO: 36); VHH-GnRH-E6 (SEQ ID NO: 37); VHH-GnRH-G10 (SEQ ID NO: 38); and VHH-GnRH-H7 (SEQ ID NO: 39).
[0213] Polypeptides selected from SEQ ID NO: 30, SEQ ID NO: 31, SEQ ID NO: 32, SEQ ID NO: 33, SEQ ID NO: 34, SEQ ID NO: 35, SEQ ID NO: 36, SEQ ID NO: 37, SEQ ID NO: 38, and SEQ ID NO: 39 are encoded by the nucleotides selected from SEQ ID NO: 58, SEQ ID NO: 59, SEQ ID NO: 60, SEQ ID NO: 61, SEQ ID NO: 62, SEQ ID NO: 63, SEQ ID NO: 64, SEQ ID NO: 65, SEQ ID NO: 66, and SEQ ID NO: 67, respectively.Docket No. 501.102. PCT
[0214] In further embodiments, the anti-GnRH VHH nanobodies comprises the CDR1, CDR2, and CDR3 sequences of any of the foregoing VHHs, optionally grafted onto an alternative VHH framework In further embodiments, the disclosure provides anti-GnRH VHH nanobodies sharing at least 80% at least 85%, at least 90%, at least 95%, at least 97%, at least 98% or at least 99% sequence identity to any of the foregoing sequences, while retaining selective binding to GnRH.
[0215] The anti-GnRH VHH and anti-FSHp VHH may comprise: soluble single-domain antibodies, fusion proteins, multivalent constructs, Fc-fusions, viral vector transgenes, or nucleic acid constructs encoding said VHHs. The VHHs may further be formulated with one or more pharmaceutically acceptable carriers, excipients, stabilizers, buffers, or adjuvants for parenteral, mucosal, oral, intranasal, intramuscular, subcutaneous, intradermal, or implantable administration.
[0216] In certain embodiments, nucleic acids encoding the disclosed VHHs are operably linked to one or more regulatory elements and incorporated into expression vectors, including without limitation viral vectors (e.g., AAV, lentivirus, adenovirus), bacterial vectors, yeast-based vectors, mRNA delivery systems, DNA delivery systems, oral bait formulations, or sustained-expression platforms suitable for delivery to a subject in need thereof.
[0217] The disclosed nanobodies may be useful in diagnostic, therapeutic, contraceptive, fertility-control, veterinary, agricultural, wildlife management, and reproductive-endocrinology applications. In certain embodiments, the VHHs may be expressed as soluble single-domain antibodies, fusion proteins, multivalent constructs, Fc-fusions, viral vector transgenes, or nucleic acid constructs encoding said VHHs.
[0218] Anti-GnRH nanobodies may be used to inhibit neutralize, sequester, or otherwise modulate endogenous gonadotropin-releasing hormone signaling, thereby reducing downstream luteinizing hormone (LH) and follicle-stimulating hormone (FSH) production. Potential applications include: fertility control and contraception in mammals; single-dose or long-acting immunocontraceptive platforms; companion animal sterilization; livestock reproductive management suppression of estrus and reproductive cycling; treatment of hormone-dependent reproductive disorders; treatment of endometriosis; treatment of uterine fibroids; treatment of polycystic ovary syndrome (PCOS); treatment of precocious puberty; treatment of benign prostatic hyperplasia (BPH); treatment of androgen-dependent disorders; treatment of estrogen-dependent disorders; treatment of hoimone-sensitive cancers, including prostate, ovarian, breast testicular, pituitary, and endometrial cancers; reduction of circulating sex steroid hormones; chemical castration applications; reproductive suppression in zoo, captive, or wild animal populations; and incorporation into viral vectors, DNA / RNA delivery systems, oral delivery systems, or implantable biologies for sustained reproductive suppression.
[0219] Anti-FSHp nanobodies may be used to inhibit neutralize, sequester, or modulate follicle-stimulating hormone signaling and associated reproductive pathways. Potential applications include: fertility control and contraception; suppression of follicular development and gametogenesis; modulation of ovarian follicle maturation; modulation of spermatogenesis; livestock breeding management companion animal contraception; treatment of infertility-associated endocrine dysregulation; treatment ofDocket No. 501.102. PCT
[0220] endometriosis; treatment of ovarian hyperstimulation; treatment of gonadal hormone disorders; treatment of hormone-responsive cancers; treatment of osteoporosis or bone-loss disorders associated with elevated FSH activity; modulation of menopausal physiology; and postmenopausal obesity hypercholesterolemia.
[0221] The disclosed anti-GnRH and anti-FSHp VHHs may additionally be utilized in: diagnostic assays; hormone detection platforms; ELISA or biosensor systems; imaging agents; affinity purification reagents; targeted delivery systems; research tools for reproductive endocrinology; combination reproductive-control therapies; species-specific contraceptive technologies; gene therapy or vectored immunoprophylactic approaches; mRNA, DNA, viral-vector, bacterial-vector, yeast-based, or probiotic delivery systems; and incorporation into recombinant biologies, Fc-fusions, multivalent constructs, viral vectors, nucleic acid delivery systems, oral bait formulations, or sustained-expression platforms.
[0222] The biological activity and therapeutic efficacy of the disclosed anti-GnRH and anti-FSHp VHH nanobodies may be evaluated in rodent models following either direct administration of purified VHH protein or vectored delivery (such as AAV) of nucleic acids encoding said VHHs.
[0223] In certain embodiments, purified VHH proteins may be administered by subcutaneous injection, including but not limited to two or more dosing events separated by an appropriate interval. In other embodiments, nucleic acid constructs encoding said VHHs may be delivered using gene therapy vectors, including adeno-associated viral (AAV) vectors, including but not limited to AAV9, via intramuscular injection as a single administration to achieve sustained in vivo expression.
[0224] Following administration, animals may be evaluated longitudinally for expression, pharmacodynamic activity, endocrine modulation, and therapeutic efficacy. Assessed parameters may indude: circulating reproductive hormone levels, including GnRH, FSH, LH, estradbl, progesterone, testosterone, inhibin, and related endocrine biomarkers; serum VHH expression levels and persistence; antibody pharmacokinetics and tissue biodistribution; histological and morphometric analysis of reproductive organs, including testes, epididymides, ovaries, uterus, prostate, seminal vesicles, and accessory reproductive tissues; gonadal weight and organ size measurements; folliculogenesis and ovarian reserve metrics; spermatogenesis and sperm quality parameters, including sperm count, motility, morphology, and viability; estrous cyde disruption and reproductive cycling alterations; mating success, conception rates, fertility suppression, and reversibility of contraceptive effect; endocrine profiles associated with infertility-related endocrine dysregulation; modulation of menopausal or postmenopausal physiology; body composition changes, induding adiposity and postmenopausal obesity-associated phenotypes; serum lipid biomarkers, including cholesterol and associated hypercholesterolemia endpoints; bone density and bone-loss phenotypes associated with elevated FSH signaling; ovarian hyperstimulation-associated phenotypes; pathological markers associated with gonadal hormone disorders; biomarkers relevant to hormone-responsive cancers; and biomarkers relevant to endometriosis and related reproductive inflammatory disorders.Docket No. 501.102. PCT
[0225] In certain embodiments, efficacy may be determined by comparison to untreated controls or positive-control agents including known anti-GnRH antibodies, GnRH antagonists, GnRH agonists, or fertility-regulating biologies.
[0226] The disclosed studies may demonstrate that administration of the anti-GnRH and / or anti-FSHp VHH nanobodies modulates reproductive endocrine signaling and produces therapeutic effects including fertility suppression, endocrine regulation, metabolic modulation, and treatment or prevention of hormone-associated disorders.
[0227] Examples
[0228] The following examples are provided to further illustrate certain embodiments and aspects of the methods disclosed herein and are notto be construed as limiting the scope of the invention.
[0229] Example 1: Construction and In Vitro Characterization of Recombinant SWPV Vectors
[0230] Attenuated SWPV strains were generated. Transfer plasmids were constructed containing expression cassettes for Green Fluorescent Protein (GFP) or for GnRH fusion proteins (STF2-GnRH or MBP-GnRH, see FIG.6) under the control of a suitable poxvirus promoter (e.g., mH5). These cassettes were flanked by SWPV DNA sequences homologous to a non-essential region (e.g., TK locus). Porcine kidney cells (PK-15) were transfected with the transfer plasmids and infected with the attenuated parental SWPV. Recombinant viruses were isolated by multiple rounds of plaque purification. Successful insertion was confirmed by PCR.
[0231] Expression of the heterologous protein was confirmed. Cells infected with the SWPV-GFP vector showed widespread green fluorescence in various porcine cell lines (Testis, Immune, Kidney, Nasal), demonstrating successful gene expression and vector tropism (FIG.3). Cells infected with SWPV-STF2-GnRH (TF10) or SWPV-MBP-GnRH (TF11 ) expressed the corresponding fusion proteins, as detected by Western blot using antibodies specific for GnRH, STF2, or MBP (FIG.4).
[0232] Example 2: In Vivo Evaluation of SWPV-GnRH Vaccines (TF10, TF11 ) in Pigs
[0233] A preliminary study was conducted in young pigs (n=6). Animals were divided into three groups: Mock-vaccinated (n=2), TF10-vaccinated (n=2), and TF11-vaccinated (n=2). Animals were monitored for clinical signs, body weight (FIG.7), and rectal temperature (FIG.8) for 30 days post-vaccination. Serum samples and swabs (skin, oral, nasal) were collected periodically.
[0234] Safety: Vaccinated animals remained healthy, gained weight comparable to mock controls (FIG.7), and showed no significant fever response (FIG.8), indicating good tolerance of the TF10 and TF11 vectors.
[0235] Immunogenicity: Serum samples were analyzed by ELISA. Both TF10 and TF11 induced detectable anti-GnRH antibody responses by Day 30 in at least some animals (FIG. 12A).Docket No. 501.102. PCT
[0236] Antibodies against the fusion partners (FHC / STF2, MBP) were also detected (FIG. 12B, FIG. 12C). Antibodies against the SWPV vector itself were induced in vaccinated animals (FIG.11A), while reactivity to control cell lysate remained low (FIG.11 B).
[0237] Biological Effect At study termination, reproductive organs were weighed.
[0238] Vector Shedding: Swab samples were analyzed by qPCR (FIG. 10A-D) to detect SWPV DNA and infectious virus, respectively. Low levels of viral DNA were occasionally detected, particularly in skin, oral, and nasal swabs shortly after vaccination. Minimal infectious virus was detected by plaque assay, suggesting limited shedding of infectious particles for these specific constructs under these conditions.
[0239] Example3: Planned Construction of Recombinant SWPV-ASFV Vaccines
[0240] Using the established methods described in Example 1, recombinant SWPV vectors expressing ASFV antigens can be constructed. Expression cassettes containing coding sequences for the five-antigen cocktail (CP204L, E183L, EP402R, B646L, B602L) or the eight-antigen cocktail (adding E199L, EP153R, F317L, MGF505-5R), driven by strong poxvirus promoters, can be inserted into non-essential loci of the attenuated SWPV genome via homologous recombination. Recombinant viruses can be plaque purified and characterized in vitro for antigen expression, replication kinetics, and genetic stability. Subsequent in vivo studies in pigs can assess safety, immunogenicity (antibody and cellular responses to ASFV antigens), and protective efficacy against virulent ASFV challenge.
[0241] Example 4: Planned Evaluation of Transmissibility
[0242] For immunocontraceptive vectors intended for wildlife population control, transmissibility will be assessed. Vectors may be further engineered to enhance shedding or environmental stability if necessary. Evaluation studies may involve vaccinating a subset of target animals (e.g., pigs or another model species) and co-housing them with unvaccinated sentinels. Transmission may be monitored by detecting vector shedding (qPCR, plaque assay) from vaccinates, and by detecting vector DNA / virus, seroconversion (anti-vector and anti-antigen antibodies), and potentially evidence of immunocontraception (e.g., hormone levels, fertility changes) in the sentinel animals overtime.
[0243] The results presented and experiments planned demonstrate the successful development of a recombinant SWPV vector platform capable of expressing heterologous antigens in vitro and in vivo. The platform shows promise for inducing desired immune responses (anti-GnRH) with good preliminary safety in the target species. This platform is readily adaptable for developing vaccines against ASFV and potentially other swine pathogens, as well as for creating species-specific immunocontraceptives for various target animals, including potentially transmissible versions for wildlife managementDocket No. 501.102. PCT
[0244] Example 5: Application of the Recombinant Poxvirus Platform to Fowlpox Virus for Avian Species
[0245] This example demonstrates the adaptability of the recombinant poxvirus vector engineering principles described herein to poxviruses specific for other host species, namely Fowlpox Virus (FWPV) for use in avian species. A recombinant FWPV vector expressing a reporter gene, Green Fluorescent Protein (GFP), was constructed and its functionality was evaluated h vitro in avian cells.
[0246] A cell-adapted strain of Fowlpox Virus served as the parental virus. An expression cassette was designed comprising the GFP coding sequence under the transcriptional control of the mH5 promoter, consistent with promoter strategies used in other examples (e.g, FIG.6). This expression cassette was inserted into the FWPV genome via homologous recombination, targeting a region between the FPV086 and FPV087 loci, presumed to be non-essential for viral replication in vitro. Standard homologous recombination techniques, similar to those described forSWPV vector construction, were employed using a transfer plasmid containing the mH5-GFP cassette flanked by sequences homologous to the FPV086 / 087 intergenic region. Recombinant FWPV-GFP virus was isolated and purified.
[0247] To assess vector function, DF1 cells, a continuous cell line derived from primary chicken embryonic fibroblasts, were cultured under appropriate conditions. The DF1 cells were infected with the generated recombinant FWPV-GFP virus. Following infection, the cells were monitored overtime using microscopy. Both fluorescence images (to detect GFP expression) and phase-contrast (brig htfield) images (to visualize the cells) were captured at 0, 1, 2, and 3 days post-infection (dpi).
[0248] The results of this experiment are shown in FIG. 13. At day 0 post-infection, minimal background fluorescence was observed. By day 1 dpi, a few fluorescent cells were detectable, indicating initial infection and onset of GFP expression. At day 2 dpi, the number of green fluorescent cells increased significantly, and foci of infection began to form, demonstrating expression of the transgene and likely replication of the recombinant virus. By day 3 dpi, these fluorescent foci had expanded notably, indicating efficient cell-to-cell spread of the recombinant FWPV-GFP vector within the DF1 cell monolayer and robust GFP expression. The corresponding brightfield images confirmed the presence of the cell monolayer throughout the time course.
[0249] These results confirmed that the genetic engineering strategies, including the use of specific promoters like mH5 and insertion via homologous recombination into non-essential regions, were applied across different genera of poxviruses relevant to specific hosts (i.e., extending beyond Suipoxvirus to Avipoxvirus). This successful generation and in vitro characterization of a recombinant FWPV vector expressing a heterologous gene in avian cells supports the broad applicability of the disclosed platform technology for developing species-specific poxvirus vectors for diverse target animals, including birds, for applications such as vaccination or potentially immunocontraception.Docket No. 501.102. PCT
[0250] Example 6: Rodent Studies Investigating MBP-GnRH Efficacy
[0251] Preclinical efficacy testing of antigens in protein vaccines was conducted in male rats. Animals received two intramuscular injections of MBP-GnRH (TF1 ) fusion, in combination with an appropriate adjuvant at a dose of 100 micrograms per injection, separated by three weeks, with evaluation at eight weeks post-initial vaccination, as depicted in FIG.4. Control animals received a vehicle alone.
[0252] As shown in FIG.15, MBP-GnRH vaccination demonstrated a 75 percent decrease in testis weight compared to control animals and other vaccine candidates (OVA Alt, Flagellin, CRM197). FIG. 16 presents detailed immunological and endocrinological data from these same animals. MBP-GnRH vaccination elicited a robust anti-GnRH antibody response, with vaccinated animals demonstrating approximately a 14-fold increase in serum anti-GnRH antibody titers relative to control animals (optical density at 450 nm: approximately 2.5 vs.0.18 in controls). Serum testosterone concentrations were dramatically suppressed in vaccinated animals, with approximately 80 percent reduction (from approximately 170 ng / dL in controls to approximately 30 ng / dL in vaccinated animals). Histological examination of testicular tissue (shown in FIG. 16 and FIG.22, panel B) revealed severe disruption of seminiferous tubule architecture, with dramatic loss of germ cells, absence of spermatids and speim, and reduced Leydig cell numbers, confirming complete cessation of spermatogenesis and testosterone production. These results demonstrated that a single round of MBP-GnRH vaccination is capable of inducing profound reproductive suppression in male rodents.
[0253] FIG.21 provides a comprehensive summary of all vaccine candidates (TF1-TF9) tested in rodent models, showing comparative efficacy data. Antigens associated with TF1 through TF8 show varying degrees of testis weight reduction (ranging from 3 percent to 30 percent), testosterone suppression (ranging from 49 percentto 88 percent), and anti-GnRH antibody generation (ranging from 9-fold to 16-fold increases). FIG.22 presents histological cross-sections of testicular tissue from vaccinated animals with five different candidates (TF1-TF5), showing the dose-dependent relationship between antigen design and severity of testicular pathology. The candidate MBP-GnRH12x (see FIG.22, Image B) demonstrated the most severe testicular atrophy and loss of germ cells.
[0254] Example 7: Porcine Studies of Swinepox Vector Safely and Immunogenicity
[0255] Safety and immunogenicity testing of Swinepox-based vaccine candidates (TF10 and TF11 ) was conducted in young pigs. As shown in FIG.24, which provides the schematic design of the TF10 and TF11 swinepox vaccine constructs and the animal study design timeline, animals received a single intramuscular injection of Swinepox-GnRH vaccine on day 0, with evaluations extending through day 30 post-vaccination. Endpoints assessed included clinical safety parameters, vector distribution and replication, anti-viral antibody responses, and antigen-specific (anti-GnRH, anti-flagellin, anti-MBP) antibody developmentDocket No. 501.102. PCT
[0256] FIG. 19 displays preliminary data from the porcine vaccine study. Vaccinated pigs maintained normal body weight gain trajectories (shown in FIG. 19, left panel, and FIG.7) and stable rectal temperatures (FIG.8) throughout the 30-day observation period, with no clinical signs of illness, systemic disease, or local injection site reactions. Swinepox vector was detected in serum and mucosal secretions (skin, oral, and nasal swabs) by qPCR and plaque assay through day 14 post-vaccination, with clearance by day 30 (FIG. 10A, FIG.10B, FIG. 10C, and FIG. 10D), demonstrating controlled, time-limited viral replication. Strong anti-Swinepox antibody titers were detected by ELISA in serum at day 30 (FIG. 11A and FIG. 11B), with minimal reactivity to porcine cell lysate controls, confirming antibody specificity to viral determinants. Vaccinated pigs exhibited robust antigen-specific antibody responses against GnRH, flagellin (FliC), and MBP by day 30 post-vaccination (FIG. 12A, FIG. 12B, and FIG 12C), demonstrating successful expression of the GnRH-fusion antigen by the viral vector and recognition of the antigen by the porcine immune system. FIG.19 right panel shows increases in anti-GnRH (Fertility Antigen) and anti-MBP (Bacteria Antigen) antibody levels from 0 dpi to 30 dpi, confirming the antigen-specific immune responses that were elicited. These results establish the safety and immunogenicity of Swinepox-based vaccines in a large animal model.
[0257] Example 8: Multi-platform GnRH Fusion Protein Vaccine Antigen Optimization and Efficacy in Rodent models This example demonstrates the adaptability of a recombinant protein platform for generating immunocontraceptive vaccines targeting gonadotropin-releasing hormone (GnRH). The platform, which comprises multiple carrier proteins (MBP, STF2, TCG13, and others) fused to tandem GnRH epitopes (9x or 10x repeats), was rapidly modified to optimize: immune tolerance, antibody specificity, and hormonal suppression while minimizing off-target responses to carrier proteins. In this example, systematic variation of protein scaffolds, repeat stoichiometry (units of GnRH to bacterial protein), and adjuvant coupling yields superior performance metrics across testis weight reduction, testosterone suppression, and GnRH-spedfic antibody induction with minimal MBP cross-reactivity.
[0258] Vaccine candidates were engineered as follows: MBP-GnRH-12x (TF1 ) comprising 12 tandem wild-type GnRH repeats fused to maltose-binding protein; STF2-GnRH-12x (TF7) comprising GnRH repeats flanked by STF2 scaffold proteins (left and right domains); TCG13 (TF6) comprising a CRM197 carrier protein appended to 13x GnRH repeals via covalent cross-linking; MG09, MG09L, MG10, MG10L (TF9-A through TF9-D) comprising MBP-based constructs with 9x or 10x GnRH repeats, optimized for expression and immunogenicity; and VHH-GnRH-206 (TF12) and AAV9-VHH (TF13) comprising nanobody-GnRH fusion (negative controls; GnRH absent from TF12 / TF13).
[0259] Male Sprague Dawley rats (n = 3-4 per vaccine group; 28 animals total including mock control) were immunized subcutaneously with 100 pg purified protein vaccine (or vehicle for mock group) at day 0 and day 28. Blood sera were collected at days 0, 30 (post-immunization), and 56; testes were collected at day 56 for histological evaluation and weight determination.Docket No. 501.102. PCT
[0260] Endpoint assays were performed that quantified testosterone, testis weight and Anti-GnRH and Anti-MBP antibodies. With respectto testosterone, serum testosterone was quantified by high-performance liquid chromatography / mass spectrometry (LC-MS), where the limit of detection (LOD) < 1 ng / dL. With respect to testis weight the testes were dissected, weighed, and expressed as absolute weight (grams) and as percent change relative to mock control; and histological sections were prepared in 10% neutral buffered formalin. With respectto Anti-GnRH and Anti-MBP antibodies, ELISA (enzyme-linked immunosorbent assay) were performed on sera diluted 1: 1280 using recombinant GnRH peptide or MBP protein as a capture antigen and optical density (OD) was measured at 450 nm. Furthermore, immunohistochemistry of testis sections was assessed for Leydig cell morphology and spermatogenic status.
[0261] The most efficacious constructs achieved complete testosterone suppression (100% reduction to < 5 ng / dL, the lower limit of quantification) relative to mock controls (mean 150-250 ng / dL).
[0262] Table 1: Testosterone Reduction
[0263]
[0264] The VHH constructs (TF12, TF13) lacking covalently integrated GnRH failed to suppress testosterone adequately, demonstrating the critical importance of direct GnRH presentation to the immune system.
[0265] Quantitative testes weight measurements (FIG.28, FIG.29, bwer FIG.30) revealed dose-dependent and construct-dependent reductions in testes mass suggesting atrophy of the testes. The most effective vaccines achieved 71-79% reduction in testes weight relative to mock controls (mean control mass -1.8 g; post-treatment range 0.3 - 0.5 g).
[0266] Table 2
[0267]
[0268] Docket No. 501.102. PCT
[0269]
[0270] Histological examination of post-treatment testes revealed Leydig cell depletion, reduced spermatogenic activity, and seminiferous tubule atrophy consistent with sustained GnRH receptor antagonism. MG09L (TF9-B) produced the most pronounced morphological changes, including near-total loss of spermatogenic capacity.
[0271] GnRH-Specific Antibody Induction and Vaccine-Carrier Selectivity was investigated by performing ELISA analysis of day-56 sera (1:1280 dilution), which demonstrated robust anti-GnRH antibody production across most vaccine constructs (FIG.33 and FIG.
[0272] 34); and expressing proteins F, E, D, G, H, I, and J led to complete suppression of testosterone. Critically, differential anti-canier (MBP) response reflected the capacity of the platform to modulate the vaccine-to-adjuvant ratio.
[0273] Table 3
[0274]
[0275] The superior performance of MG09L (GnRH: carrier ratio 9.3:1) and TCG13 (ratio 16.7:1) over the initial MBP-GnRH-12x construct (ratio 2.75: 1 ) indicates that optimization of epitope density and carrier architecture reduces MBP cross-reactivity while maintaining or enhancing GnRH-specific responses. This finding is significant for platform adaptability: the same carrier-epitope design principles can be applied to alternative antigens (ASFV epitopes, for example) while maintaining high antigen specificity with minimal off-target immunity.
[0276] All vaccinated animals maintained normal body weight trajectories throughout the 56-day observation period (FIG.31), tracking with mock controls. No overt signs of systemic toxicity, autoimmunity (e.g, no anti-MBP antibodies in cerebrospinal fluid), or off-target organ pathology were observed. This demonstrates that the platform herein achieves specific reproductive suppression without generalized immunotoxicity.
[0277] This Example demonstrates that the recombinant GnRH-ftision protein platform is highly adaptable across multiple earner scaffolds (MBP, STF2, TCG13) and epitope densities (9x, 10x, 12x, 13x repeats), enabling systematic optimization ofDocket No. 501.102. PCT
[0278] contraceptive efficacy without major re-engineering, wherein the scaffolds led to decrease in testes weight (42-79% decrease in testes weight); complete suppression or near complete suppression of testosterone (97-100% suppression of testosterone); substantially enhanced anti-GnRH antibody responses (at least 8x higher levels of anti-GnRH antibody); and enhanced anti-MBP antibodies. The modularity of the platform is evident from the following conclusions (C1, C2, C3, and C4).
[0279] (C1) Scaffold flexibility: MBP, STF2, and TCG13 all produced functional immunocontraceptives with comparable or superior performance to the original MBP-GnRH-12x design.
[0280] (C2) Epitope density tuning: Progressive refinement from 9x to 13x GnRH repeats, combined with canier variation, identified MG09L as a lead candidate with 100% testosterone suppression, 79% testis atrophy, and a 9.3:1 GnRH-to-carrier antibody response exhibited higher selectivity compared to the control;
[0281] (C3) Rapid iterative optimization: Nine distinct constructs were synthesized, expressed, and evaluated in a single animal cohort (28 animals, 56 days), confirming the efficiency of the platform for antigen discovery.
[0282] (C4) Pathogen adaptation potential: The demonstrated flexibility in epitope presentation and canier selection indicates that heterologous antigens (e.g, ASFV structural proteins, other viral epitopes) can be rapidly integrated into the same platform with minimal modification.
[0283] Example 9: Safety and In Vivo Replication of Volepox Virus-Based Immunocontraceptive Vector in Rodent Model
[0284] Viral vector delivery of immunocontraceptive antigens offers theoretical advantages over protein-only vaccines: sustained antigen expression, dose-independent efficacy, and potential for self-spreading transmission in field populations. This Example describes the engineering and preliminary evaluation of Volepox Virus (VPXV), a naturally rodent-specific poxvirus, as a replication-competent vector for GnRH immunocontraceptive antigens. The vector was attenuated by directed deletion of one or more of genes 1-11, which were viral immunomodulatory genes, to eliminate overt pathogenicity while preserving replication capacity. A transgene encoding firefly luciferase (Photinus pyralis) was integrated to enable non-invasive whole-body imaging of viral dissemination and replication kinetics in infected rodents. (See FIG.36.) Genes 12-20 can also be deleted from or modulated within the VPXV.
[0285] A Volepox Virus (VPXV) strain D-11 expressing firefly luciferase was employed. The vector was engineered to: express a codon-optimized firefly luciferase gene under control of a vaccinia virus p7.5 early-late promoter; harbor deletions of 11 immunomodulatory genes (including viral interleukin-10 homologues, NF-KB inhibitors, and apoptosis suppressors) to achieve attenuation; maintain full replication capacity in mammalian cell culture (BHK-21 cells) and in rodent tissues Virus slock titer was 2.6 x 106 PFU / mL as determined by plaque assay on BHK-21 monolayers.Docket No. 501.102. PCT
[0286] Male Sprague Dawley rats (n = 20; Charles River; age ~6 weeks at study initiation) were randomly assigned to five groups (n = 4 per group). Group 1 was a PBSmock (negative control, vehicle only); Group 2 was 1 x 10³ PFU VPXV-D11-Luc; Group 3 was 1 x 10⁴ PFU VPXV-D11-Luc; Group 4 was 1 x 10⁵ PFU VPXV-D11-Luc; and Group 5 was 1 x 10⁶ PFU VPXV-D11-Luc Virus was delivered intramuscularly (IM) in the right quadriceps in 100 pL phosphate-buffered saline per animal.
[0287] Endpoint assays and observations were performed that involved clinical monitoring and bioluminescence imaging, respectively. With respectto clinical monitoring, body weight and rectal temperature were recorded daily (days 0-6) and at intervals thereafter (3x / week, days 7-30). Animals were observed for signs of illness, behavioral abnormality, or localized injection-site reactions (b) Bioluminescence imaging: Whole-body optical imaging via IVIS Spectrum (PerkinElmer) was performed on days 2 and 5 postinfection. Animals were anesthetized with isoflurane, injected intraperitoneally (IP) with D-luciferin (150 mg / kg, 10 mL / kg volume) at 15 min (days 2 and 5) and 3 hours (day 5 only) post-luciferin delivery. Photon flux was measured from regions of interest (abdominal and thoracic cavity) and from whole-body signal. Signal intensity is a proxy for viral replication and antigen expression at infected tissue sites. Tissues (testes, spleen, liver, lung) were collected from select animals on days 2 and 5 post-infection, fixed in 10% neutral buffered formalin, sectioned at 5 pm, and stained with hematoxylin & eosin (H& E). Lesions were graded semi-quantitatively for inflammation, necrosis and viral cytopathic effect Safety protocols designated scheduled euthanasia on day 6 (all groups); organs were examined grossly for evidence of systemic viral spread (hemorrhage, consolidation, necrotic foci) prior to the planned 30-day terminal timepoint
[0288] Overthe 6-day acute observation period, all 20 animals remained clinically healthy with no mortality. Body weight gain was normal across all groups baseline mean weights were 226-235 g; by day 6, animals gained 25-35 g on average, consistent with age-appropriate growth (see FIG.37 and FIG.38). Rectal temperature remained stable in all groups (~100-101 °F [37.8— 38.3°C]; FIG 39), with no fever, hypothermia, or temperature oscillations. No injection-site swelling, abscess formation, ulceration, or systemic signs of infection (piloerection, lethargy, reduced food intake) were noted even in high-dose animals (1 x 106 PFU). These findings indicate that the attenuated VPXV vector was well-tolerated in rodents across a >105-fold dose range, with no overt signs of acute toxicity, immunosuppression, or systemic inflammatory disease.
[0289] Optical imaging revealed robust bioluminescence signals from all infected animals, confirming active viral replication and luciferase transgene expression. Signal was localized to the injection site (right hindquarters) and spread to distal tissues over the 5-day imaging window.
[0290] At Day 2 Post-Infection (FIG.40), photon flux from injected-leg and abdominal regions led to average radiance where PBS-mock (negative control, vehicle only) was lower than 10⁵ PFU VPXV-D11-Luc delivered intramuscularly (IM) in the right quadriceps in 100 µL phosphate-buffered saline per animal.Docket No. 501.102. PCT
[0291] At Day 5 Post-Infection, 15-min Timepoint (FIG.41), peak photon flux (15 min post-luciferin injection) had average radiance of 1 x 10⁵ PFU VPXV-D11-Luc comparable to day 2, indicating sustained viral replication without apparent plateau or decline by the early post-infection timepoint
[0292] Day 5 Post-Infection, 3-Hour Delayed Timepoint (FIG.42), a delayed (3-hour) imaging timepoint on day 5 was acquired to assess signal distribution and clearance kinetics. Bioluminescence at 3 hours post-luciferin showed sustained, high-level luciferase expression from viral-infected tissues. This extended signal retention is consistent with continuous viral replication and antigen production over the 5-day window.
[0293] Collectively, the bioluminescence data from FIG.40, FIG.41, and FIG.42 demonstrate that the attenuated VPXV vector replicates efficiently in rodent tissues and sustains transgene (luciferase) expression for at least 5 days post-infection, with no evidence of systemic viral dissemination (signal remained localized to injection site and regional lymph drainage pathways) or pathogenic viral kinetics.
[0294] Tissue sampling on days 2 and 5 revealed focal, self-limited inflammatory lesions at the injection site (Figure 30 qualitative descriptor) consistent with early viral infection and host immune activation. Spleen, liver, and lung showed no evidence of systemic viral dissemination (no local necrosis, no viral cytopathic effect outside the injection site). Testes were histologically normal across all groups at day 6, confirming that early-stage VPXV infection does not elicit overt direct testicular pathology or unintended endocrine disruption independent of intended antigen expression. These findings validate the safety profile of the vector in the target tissue environment
[0295] This Example demonstrated Volepox Virus was a replication-competent immunocontraceptive vector in a rodent model. The data supported the following conclusions, C6, C7, C8, C9, and C10.
[0296] (C6) Attenuation is effective and reversible: Deletion of 11 immunomodulatory genes rendered the virus non-lethal and non-pathogenic in immunocompetent adult rodents, yet replication capacity was fully preserved. This balance— loss of virulence without loss of productive infection— is essential for a transmissible vaccine vector.
[0297] (C7) Sustained antigen expression in vivo: Luciferase activity over 5 days demonstrates that the integrated transgene was stably expressed during active viral replication. This validated the capacity of the platform herein to deliver and maintain expression of heterologous immunocontraceptive antigens (GnRH fusion proteins) or other pathogen-derived antigens in infected tissues. (C8) Dose-independent kinetics: Viral replication scaled with inoculum dose-response, confirming rational control over vector dose in natural field settings.Docket No. 501.102. PCT
[0298] (09) Localized infection pattern: Signal remained restricted to the injection site and regional nodes, with no evidence of systemic dissemination on day 5. This was consistent with early-phase viral replication prior to potential host-to-host transmission (if the vector is engineered for transmissibility).
[0299] (C10) Platform readiness for next-stage development The successful replication of attenuated VPXV in rodents establishes the technical foundation for integration of GnRH or other contraceptive antigens into the viral genome; dose-response studies to correlate viral burden with immunocontraceptive efficacy; and evaluation of transmissibility in controlled co-housing experiments (sentinel animal design); and extension to natural host species (wild rats, wild boar) for field pilot studies.
[0300] Example 10: Antigen Sourcing, Preparation, and Pre-Panning Plate-Binding Assessment
[0301] Recombinant antigens were obtained for use in positive and negative selection. His-tagged GnRH (50 pg) was used as the positive selection antigen for panning Rounds 1 and 2. OVA-fused GnRH (150 pg) was obtained from Cloud-Clone Corp, and used as the positive selection antigen for panning Rounds 3 and beyond. His-tagged FSH (200 pg) was used as the positive selection antigen for FSHp panning. An FSHp-derived peptide fragment designated FSHpepI (4 mg) was an alternative positive selection antigen in FSHp panning rounds.
[0302] Antigens used for positive selection were His-tagged, with the exception of OVA-GnRH. Antigens were coated in Bio-Rad coating buffer (BUF030A) at pH 7.8-8.2. Wash buffer was phosphate-buffered saline supplemented with Tween-20 (PBS-Tween) at pH 7.4, and washes were performed at room temperature. For GnRH, negative selection was performed against ovalbumin (OVA) to remove any non-specific OVA binders. For FSHp, at least one round of negative selection was performed against bovine serum albumin (BSA), OVA or a similar protein to remove non-specific binders.
[0303] Prior to panning, antigens were evaluated by ELISA to confirm adsorption to the microtiter plates intended for use in panning. Antigens were coated at 100 pL per well at 10 pg / mL or 1 pg / mL in Bio-Rad coating buffer overnight at 4 °C, and were detected with an anti-His-HRP secondary antibody. Good adsorption of FSH was observed at both 10 pg / mL and 1 pg / mL coating concentrations. Good adsorption of GnRH was observed at 10 pg / mL but not at 1 pg / mL. (See FIG.43.)
[0304] Example 11: Iterative Phage-Display Biopanning
[0305] A synthetic phage-displayed VHH library was subjected to iterative roundsof biopanning against GnRH antigens under increasingly stringent selection conditions. For GnRH, panning was initially performed using His-tagged GnRH, followed by OVA-fosed GnRH, with counterselection against OVA and unrelated proteins. A total of six rounds of panning were performed, beginning with two rounds on GnRH-His followed by four rounds on OVA-GnRH with negative selection on OVA BSA and / or non-fat dry milk (NFDM). Antigen amount negative selection, and input / recovered phage titers for each round were as follows.Docket No. 501.102. PCT
[0306] Table 4
[0307]
[0308] At Round 5, parallel panning was performed on OVA and on OVA-GnRH to gauge off- and on-target enrichment Recovered phage from OVA panning was approximately 108, as compared with 2.5 x 109on OVA-GnRH, evidencing approximately 10-fold target-specific enrichment This trend was further reflected in a phage ELISA which showed preferential binding to GnRH-OVA, albeit with elevated background. NGS analysis likewise showed specific VHH sequences increasing in abundance with each round of panning, with the most abundant sequence at approximately 2% of the population.
[0309] These results indicated that GnRH-specific binders existed in the phage pool. One additional round of panning was performed with more stringent negative selection (OVA BSA, and NFDM in Round 6) to ensure thaton-target sequences were sufficiently enriched prior to screening of 94 colonies. (See FIG.44.)
[0310] Example 12: Iterative Phage-Display Biopanning Against FSH
[0311] In parallel, the synthetic phage-displayed VHH library was subjected to iterative rounds of biopanning against FSHp antigens. For FSH, panning strategies used a full-length His-tagged FSHβ protein. Rounds of panning were performed by taking the output from a panning applied to FSHb-His, with BSA-His used for negative selection (designated Rounds 3(His) and 4(His)).
[0312] Table5
[0313]
[0314] Docket No. 501.102. PCT
[0315] These rounds yielded the increase in recovered phage. A phage ELISA performed with the pooled Round 4 (His) library showed significant enrichment on FSH, with little to no background signal on BSA These results indicated that the phage pool was enriched for FSH binders, and the Round 4 (His) phage pool was used to select single clones for ELISA screening. (See FIG.45.)
[0316] Example 13: ELISA Screening of 94 GnRH Clones
[0317] A total of 94 phage clones were screened from the GnRH panning campaign by ELISA against target and off-target control antigens to identify clones exhibiting preferential binding and reduced nonspecific background. A supernatant containing secreted phage displaying a unique VHH was applied to each well, and an anti-g8p-HRP secondary antibody was used as a reporter.
[0318] Two controls were included on each plate: a negative control in well G12, in which GnRH-OVA was coated and no VHH was applied, to confirm antigen coating; and a negative control in well H12, in which no protein was coated (other than blocker), to confirm adequate well blocking. The ELISA was performed on two plates— one coated with 100 pL of GnRH-OVA at 5 pg / mL, and the other coated with 100 pL of OVA at 5 pg / mL. Clones were ordered by fold signal increase between the on-target (GnRH-OVA) and off-target (OVA) plates.
[0319] Several apparent on-target binders were observed, although a substantial fraction of the pool appeared non-specific for GnRH (consistent with the pooled phage ELISA result). Colonies were selected for sequencing on the basis of fold signal between the on-and off-target wells. (See FIG.46.)
[0320] Example 14: ELISA Screening of 94 FSH Clones
[0321] A total of 94 phage clones were screened from Round 4 (His) of the FSH panning campaign by ELISA against target and off-target control antigens. A supernatant containing secreted phage displaying a unique VHH was applied to each well, and an anti-g8p-HRP secondary antibody was used as a reporter.
[0322] Two controls were included on each plate: a positive control in well G12, in which FSH was coated, no VHH was applied, and an anti-His-HRP antibody was applied to confirm antigen coating; and a negative control in well H12, in which no protein was coated, to confirm adequate well blocking. The ELISA was performed on two plates— one coated with 100 pL of FSHB-His at 5 pg / mL, and the other coated with 100 pL of BSA-His at 5 pg / mL.
[0323] An abundance of on-target binders was observed, with only a single clone exhibiting non-specific binding to BSA-His. Because FSHp signal was largely saturating, clones were selected for sequencing among target-specific wells using distributed spatial sampling across the plate, in addition to fold signal between the on- and off-target wells. (See FIG.47.)
[0324] Example 15: Sanger Sequencing and Identification of Unique VHH ClonesDocket No. 501.102. PCT
[0325] Sequencing analysis of enriched clones, together with next-generation sequencing (NGS)-based cluster analysis of phage pools across panning rounds, identified multiple unique VHH binders enriched during selection.
[0326] For FSH|3, at least eighteen (18) unique and previously unidentified VHH amino acid sequences were identified, as well as additional NGS-defined sequence clusters. These VHH molecules demonstrated selective binding to FSH relative to control proteins and represent novel antigen-binding compositions directed against the beta subunit of follicle-stimulating hormone. The clones VHH-FSHB-B4, VHH-FSHB-B7, VHH-FSHB-C7, VHH-FSHB-D3, VHH-FSHB-D7, VHH-FSHB-D8, VHH-FSHB-D9, VHH-FSHB-D10, VHH-QBI-FSHB-E7, VHH-FSHB-E11, VHH-FSHB-F3, VHH-FSHB-F7, VHH-FSHB-F11, VHH-FSHB-G5, VHH-FSHB-G7, and VHH-FSHB-H2 were identified by Sanger sequencing of selected colonies, and the additional sequences designated VHH-FSHB-Cluster 12 and VHH-FSHB-Cluster 20 were identified by NGS analysis as dominant clusters not recovered by Sanger sequencing of the screened plate.
[0327] For GnRH, at least ten (10) unique and previously unidentified VHH amino acid sequences were identified, and additional NGS-enriched sequence clusters were identified. These nanobodies demonstrated preferential binding to GnRH-fused antigens relative to unfused controls, supporting target specificity. The clones VHH-GnRH-B3, VHH-GnRH-B5, VHH-GnRH-B7, VHH-GnRH-C5, VHH-GnRH-C9, VHH-GnRH-D3, VHH-GnRH-E6, VHH-GnRH-G10, and VHHGnRH-H7 were identified by Sanger sequencing, and the additional sequence designated VHH-GnRH-Cluster 53 was identified by NGS analysis. The identified VHHs comprise distinct complementarity-determining region (CDR) sequences and framework combinations not previously reported.
[0328] The full-length amino acid sequences of the identified clones, as indicated above (SEQ ID NOs: 12-40), include framework regions characteristic of camelid VHH domains together with CDR1, CDR2, and CDR3 loops unique to each clone, and a C-terminal hexahistidine tag-containing extension (GPGGQHHHHHHGAS) used to facilitate purification. (See FIG.48.)
[0329] Example 16: Next-Generation Sequencing (NGS) Cluster Analysis
[0330] Phagemid minipreps were prepared from phage-infected E. coli after each round of panning and were subjected to shallow nextgeneration sequencing on a Nanopore platform, with approximately 200 to 1,000 reads per sample. Complementarity-determining regions (CDRs) were extracted from each read and were organized into clusters by density-based clustering, with each cluster representing a unique VHH sequence. Cluster abundance was determined by dividing the number of reads in a given duster by the total number of reads in the sample.
[0331] For GnRH, in rounds 5 and 6 of panning, phage was applied to both the GnRH-OVA fusion and to unfused OVA and the phage output of both was sequenced. Differential signal between on- and off-target sequencing samples informed the assignment of binders that prefer GnRH versus general protein binders. NGS cluster analysis confirmed enrichment of specific clusters acrossDocket No. 501.102. PCT
[0332] Rounds 3 through 6, including Cluster 53, which was identified by NGS but was not recovered among the Sanger-sequenced colonies. Top GnRH clusters identified included Cluster 53, Cluster 183, Cluster 186, Cluster 121, and Cluster 111. (See FIG.48.) For FSHp, rounds 3 and 4 were initially performed on the FSH0 peptide fragment ('pep 1 "). After poor enrichment was observed, those rounds were repeated on the full-length His-tagged protein. NGS cluster analysis of the FSHp panning campaign demonstrated marked enrichment of specific CDR clusters in the Round 3 and Round 4 (His) samples relative to the pep 1 samples, including clusters designated Cluster 1, Cluster 13, Cluster 12, Cluster 20, Cluster 17, Cluster 7, and Cluster 83. Among these, Cluster 12 and Cluster 20 were identified as dominant by NGS but were not recovered from Sanger sequencing of selected wells, and are accordingly disclosed as separate sequences VHH-FSHB-Cluster 12 and VHH-FSHB-Cluster 20. (See FIG.49.) Example 17: Further Characterization of Selected Clones
[0333] The identified clones are amenable to further characterization to determine affinity for the target protein, neutralizing capacity, and to map the location of the binding site, thereby enabling ranking of the VHH clones. Accordingly, additional testing of the disclosed clones may include, without limitation, single-concentration ELISA performed in replicates to confiim target binding and specificity; dose-response ELISA to estimate apparent affinity; biolayer interferometry (BLI) or surface plasmon resonance (SPR) to obtain quantitative binding kinetics and affinity parameters (km, kar, KD); epitope mapping; and functional validation in the intended application, including in vitro signaling assays, ex vivo gonadotrope assays, and in vivo immunocontraceptive or hormone suppression studies. Production of purified or tagged single-domain antibodies (sdAbs) or VHH-Fc constructs from any of the disclosed sequences may be carried out by recombinant expression in bacterial (e.g., E. coli), yeast, mammalian, or insect cell systems using methods well known in the art
[0334] Enumerated Embodiments
[0335] A recombinant poxvirus comprises: a heterologous nucleic acid sequence encoding at least one polypeptide selected from the group consisting of an African Swine Fever Virus (ASFV) antigen and an immunocontraceptive antigen, wherein the recombinant poxvirus is capable of infecting cells of a target animal spedes; wherein the poxvirus is a species-specific poxvirus selected for the target animal species; wherein the target animal species is swine and the poxvirus is a Swinepox Virus (SWPV); wherein the poxvirus is attenuated relative to a corresponding wild-type poxvirus; wherein the heterologous nucleic acid sequence encodes at least one ASFV antigen; wherein the heterologous nucleic add sequence encodes a plurality of different ASFV antigens; wherein the plurality of different ASFV antigens comprises at least five antigens selected from the group consisting of CP204L, E183L, EP402R, B646L, B602L, E199L, EP153R, F317L, and MGF505-5R; wherein the heterologous nudeic acid sequence encodes at least one immunocontraceptive antigen; wherein the immunocontraceptive antigen induces an immune response against Gonadotropin-Releasing Hormone (GnRH) or a Zona Pellucida (ZP) protein in the target animal spedes; wherein the immunocontraceptive antigen is a fusion protein comprising GnRH operably linked to a carrier protein or adjuvant; wherein theDocket No. 501.102. PCT
[0336] carrier protein is Maltose-Binding Protein (MBP) or a flagellin protein (FliC / STF2); wherein the recombinant poxvirus comprises a first heterologous nucleic acid sequence encoding at least one ASFV antigen and a second heterologous nucleic acid sequence encoding at least one immunocontraceptive antigen; wherein the recombinant poxvirus is capable of transmission between individuals of the target animal species; wherein the heterologous nucleic acid sequence is inserted into a non-essential region of the poxvirus genome.
[0337] A composition comprising the recombinant poxvirus and a veterinarily acceptable carrier, formulated as a vaccine or an immunocontraceptive agent
[0338] A method induces an immune response against African Swine Fever Virus (ASFV) in a swine subject wherein the method comprises: administering an effective amount of the composition comprising the recombinant poxvirus and the veterinarily acceptable carrier, formulated as the vaccine or the immunocontraceptive agent wherein the recombinant poxvirus comprises a heterologous nucleic acid sequence encoding at least one ASFV antigen.
[0339] A method of inducing immunocontraception in an animal subject wherein the method comprises: administering an effective amount of the composition comprising the recombinant poxvirus and the veterinarily acceptable carrier, formulated as the vacdne or the immunocontraceptive agent wherein the recombinant poxvirus comprises a heterologous nucleic acid sequence encoding at least one immunocontraceptive antigen, wherein the animal subject is selected from the group consisting of swine, canids, felids, rodents, lagomorphs, equids, cervids, and camelids, and wherein the recombinant poxvirus is selected for species-specificity to the animal subject
[0340] A method of controlling a population of wild or feral animals, wherein the method comprises: administering the composition comprising the recombinant poxvirus and the veterinarily acceptable carrier, formulated as the vaccine orthe immunocontraceptive agent to a subset of animals within the population, wherein the recombinant poxvirus comprises a heterologous nucleic acid sequence encoding at least one immunocontraceptive antigen and wherein the recombinant poxvirus is capable of transmission between individuals of the animal population.
[0341] An immunocontraceptive vaccine platform induces infertility in vertebrate pest species, wherein the immunocontraceptive vaccine comprises: (a) a protein antigen comprising gonadotropin-releasing hormone (GnRH) fused to an immunogenic protein carrier selected from the group consisting of Maltose-Binding Protein (MBP), Flagellin (STF2), and CRM197 (inactive diphtheria toxin); and (b) a species-specific viral vector for delivery, selected from the group consisting of attenuated Volepox Virus for rodents and attenuated Swinepox Virus for swine; wherein the protein antigen is selected from: TF1 (MBP-12xGnRH), TF2 (GnRH12x-MBP), TF3 (MBP-GnRH12xmut), TF4 (MBP-intemal GnRH12x), TF5 (MBPmut-GnRHI 2x), TF6 (CRM197-13xGnRH, also designated TCG13), TF7 (S7F2-12xGnRH), TF8 (VHH-GnRH-206), and TF9 (MG09L or MBP-based variant); whereinDocket No. 501.102. PCT
[0342] GnRH peptides are inserted at positions within Maltose-Binding Protein selected from: 32, 33, 74, 101, 122, 166, 185, 240, 253, and 317, with a single insertion (1 ) or double insertions (2) at selected positions, and optionally incorporating SGG flexible linker sequences.
[0343] More particularly, these polypeptides are encoded by the following polynucleotide sequences where the insertion positions (32, 33, 74, 101, 122, 166, 185, 240, 253, and 317) are adjacent to one or two underscores ( ) and the single insertion and double insertions are indicated with a “1 ” or a “2’ adjacent to one or two underscores, such as: SEO ID NO: 1 (CRM197-MBPsp_TCG13_TMD) has 1062 amino acids, as encoded bySEQ ID NO: 68; SEQ ID NO: 2 (MBP- 32_1 _74_1 J 01 J J 22 J J 66J J 85_1 _240_1 _253 _1_317_1 ) ha; 460 amino acids, as encoded by SEQ ID NO: 69; SEQ ID NO: 3 (MBP-32_1_74_1 _101 J J 22 J J 66 J _185_1_240_1_253_1_317_1_SGG) has514anino adds, as encoded by SEQ ID NO: 70; SEQ ID NO: 4 (MBP-122_2_166_2 J 85_2_240_2_317_2_SGG) has 530 amino acids, as encoded bySEQ ID NO: 74; SEQ ID NO: 5 (MBP-122_2_166_2_185_2_240_2_317_2) has470 amino adds, as encoded bySEQ ID NO: 73; SEQ ID NO: 6 (MBP-166_2_317_2) has410 amino acids, as encoded bySEQ ID NO: 75; SEQ ID NO: 7 (MBP- 166_2_317_2_SGG) has 434 amino adds, as encoded by SEQ ID NO: 76; SEQ ID NO: 8 (MBP-GnRH12x) has 518 amino acids, as encoded by SEQ I D NO: 77; SEQ I D NO: 9 (MBP-32 _1_122 J J 66 J _253 _1 _317 J ) has 420 amino acids, as encoded bySEQ ID NO: 71; SEQ ID NO: 10 (MBP-32J J 22 J J 66_1_253_1_317_1_SGG) has 450 amino acids, as encoded by SEQ ID NO: 72; and SEQ ID NO: 11 (STF2-Cd33-STF2-12xGnRH- VID) has 716 amino acids, as encoded by SEQ ID NO: 78.
[0344] A method induces long-term infertility in a vertebrate pest animal, where the method comprises: administering a single dose of the immunocontraceptive vacdne orally or by intramuscular injection, allowing cellular uptake and viral-mediated delivery of nudeotide sequences encoding the protein antigen within 3 to 10 days, and permitting the animal's immune system to mount an anti-GnRH antibody response that neutralizes native GnRH, thereby suppressing FSH and LH and inhibiting reproductive function.
[0345] A viral vector delivers of an immunocontraceptive antigen, wherein the viral vector comprises an attenuated poxvirus engineered to express a marker protein detectable exclusively in target species cells, encapsulating nucleotide sequences encoding a GnRH-immunogenic protein fusion; wherein the poxvirus is a Volepox Virus with genes 1 -11 thereof (see above) deleted for species-specific delivery to rodents; wherein the poxvirus is attenuated Swinepox Virus for species-specific delivery to swine.
[0346] A method performs a structure-guided design of a protein antigen for GnRH immunocontraception, wherein the method comprises: performing secondary structure prediction on a scaffold protein to identify surface-exposed regions; conducting comparative structure modeling using MODELLER; validating designs using AlphaFold2 to confirm structural integrity andDocket No. 501.102. PCT
[0347] surface accessibility; performing molecular dynamics simulations using AMBER to assess protein stability, peptide flexibility, and epitope presentation.
[0348] A gene therapy construct induces contraception in vertebrate pest animals, wherein the construct comprises an adeno-associated virus (AAV) vector carrying nucleotide sequences encoding: a constitutive promoter (CBA), a secretory signal peptide (SSP), a Kozak translation initiation sequence, a variable domain of a heavy-chain-only antibody targeted to GnRH, regulatory elements including a WPRE and polyadenylation signal.
[0349] A method controls population of invasive vertebrate pests, wherein the method comprises: orally distributing baited vaccine doses of the immunocontraceptive vaccine platform to a target pest population, enabling single-dose-induced long-term infertility without individual animal handling, vector persistence, or environmental accumulation of lethal compounds.
[0350] Definitions
[0351] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
[0352] The term "poxvirus" refers to any virus belonging to the family Poxviridae, a family of large, complex, enveloped DNA viruses that replicate primarily in the cytoplasm of host cells. Examples include Orthopoxvirus (e.g., Vaccinia virus), Parapoxvirus, Avipoxvirus, Capripoxvirus, Leporipoxvirus, Suipoxvirus (e.g., Swinepoxvirus), and Mollus poxvirus.
[0353] The term "vector"' or "viral vector"' refers to a virus particle that has been genetically engineered to carry and deliver foreign genetic material (e.g, DNA or RNA encoding a heterologous polypeptide) into a host cell or organism.
[0354] The term "recombinant poxvirus" refers to a poxvirus whose genome has been modified by the introduction of foreign genetic material (e.g, a gene encoding an antigen or immunomodulatory protein) and / or by the deletion or modification of endogenous viral genes (e.g., for attenuation).
[0355] " Swinepox Virus" or " SWPV refers to the species of poxvirus within the Suipoxvirus genus that naturally infects swine (pigs, Sus scrofa).
[0356] " Heterologous polypeptide" or "heterologous antigen" refers to a polypeptide or antigen that is not normally encoded by the wildtype poxvirus vector genome. This includes antigens from other pathogens (like ASFV), self-antigens used for immunocontraception (like GnRH), reporter proteins (like GFP), or adjuvant molecules.Docket No. 501.102. PCT
[0357] " Antigen" refersto a molecule capable of inducing an immune response, particularly the generation of antibodies or cell-mediated immunity.
[0358] " Immunocontraception" refers to the use of the immune system to prevent reproduction. Typically involves vaccination against proteins or hormones essential for reproduction (e.g., GnRH, ZP proteins), leading to infertility.
[0359] 'T ransmissible vaccine" or "self-disseminating vaccine" refers to a vaccine, typically based on a live replicating vector, that can spread horizontally tram vaccinated individuals to unvaccinated individuals within the same population through natural contact or shedding.
[0360] " Attenuated" refers to a virus that has been weakened or modified such that it causes less disease or pathology in the host compared to the wild-type or parental virus strain, while still being capable of replication to some extent and inducing an immune response. Attenuation can be achieved through methods Ike serial passage, targeted gene deletion, or insertion into non-essential genomic regions.
[0361] " Operably linked" refers to a juxtaposition wherein the components described are in a relationship permiting them to function in their intended manner. For example, a promoter is operably linked to a coding sequence if it controls the transcription of the sequence.
[0362] " Effective amount' refers to an amount of a recombinant poxvirus or composition thereof sufficient to elicit a desired biological response in the subject such as the induction of a protective immune response against a pathogen or the induction of immunocontraception.
[0363] " Subject1or "animal" refers to any member of the animal kingdom. In the context of this invention, subjects are typically mammals, including but not limited to swine (domestic pigs, wild boar, feral hogs), canids (dogs, coyotes, wolves), felids (cats), rodents (rats, mice), lagomorphs (rabbits, hares), equids (horses, asses), cervids (deer), camelids (camels), and potentially birds for avian-specific vectors.
[0364] " Pharmaceutically acceptable earner" or "veterinarily acceptable carrier" refers to a carrier medium that does not interfere with the effectiveness of the biological activity of the active ingredient (the recombinant poxvirus) and is not toxic to the host or subject Examples include saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof.
[0365] " ASFV" refers to African Swine Fever Virus.Docket No. 501.102. PCT
[0366] " Complementarity-determining region" or " CDR" refers to toe hypervariable loops of an immunoglobulin variable domain that primarily contact antigen, identified herein in accordance with conventional VHH numbering schemes such as Kabat, Chotoia, IMGT, or AbM. Bolded and underlined residues in toe sequences disclosed herein denote CDR1, CDR2, and CDR3 from N- to C-terminus, respectively.
[0367] " FSHP" refers to the beta subunit of follicle-stimulating hormone, including recombinant human FSHp, His-tagged FSHp, and FSHp-derived peptide fragments.
[0368] " GnRH" refers to Gonadotropin-Releasing Hormone, including the mammalian decapeptide and fusions thereof such as ovalbumin (OVA)-fused GnRH and His-tagged GnRH.
[0369] " GFP" refers to Green Fluorescent Protein.
[0370] " MBP" refers to Maltose-Binding Protein.
[0371] " STF2" refers to Salmonella Typhimurium flagellin type 2 or a derivative thereof, potentially used as an adjuvant or fusion partner.
[0372] " VHH," "single-domain antibody," "sdAb," and "nanobody" are used interchangeably herein to refer to the variable domain of a heavyrchain-only antibody capable of antigen recognition in toe absence of a light chain.
[0373] " ZP" refers to Zbna Pellucida proteins.
Claims
1. Docket No. 501.
102. PCTClaims1. A recombinant poxvirus comprising a heterologous nucleic add sequence encoding at least one immunocontraceptive antigen, wherein the at least one immunocontraceptive antigen comprises a Gonadotropin-Releasing Hoimone (GnRH) peptide fused to an immunogenic bacterial earner protein.
2. The recombinant poxvirus of claim 1, wherein the immunogenic bacterial canier protein is selected from the group consisting of Maltose-Binding Protein (MBP), Flagellin (STF2), and CRM197.
3. The recombinant poxvirus of claim 2, wherein the GnRH peptide is present in at least 9 tandem repeals.
4. The recombinant poxvirus of claim 3, wherein the GnRH peptide is present in 12 or 13 tandem repeats.
5. The recombinant poxvirus of claim 1, wherein the poxvirus is a spedes-spedfic poxvirus adapted for replication exdusively in a target animal species.
6. The recombinant poxvirus of claim 5, wherein the target animal species is swine and the poxvirus is an attenuated Swinepox Virus (SWPV).
7. The recombinant poxvirus of claim 5, wherein the target animal spedes is a rodent and the poxvirus is an attenuated Volepox Virus (VPXV).
8. The recombinant poxvirus of claim 7, wherein the Volepox Virus comprises deletions in eleven viral immunomodulatory genes to ensure attenuation while maintaining replication competence.
9. The recombinant poxvirus of claim 1, wherein the heterologous nudeic acid sequence encodes a protein antigen, wherein the protein antigen comprises: a polynucleotide sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7, SEQ ID NO: 8, SEQ ID NO: 9, SEQ ID NO: 10, and SEQ ID NO: 11.
10. The recombinant poxvirus of claim 1, further comprising a second heterologous nudeic add sequence encoding a plurality of African Swine Fever Virus (ASFV) antigens.
11. The recombinant poxvirus of claim 10, wherein the plurality of ASFV antigens comprises at least five antigens selected from the group consisting of CP204L, E183L, EP402R, B646L, B602L, E199L, EP153R, F317L, and MGF505-5R.Docket No. 501.
102. PCT12. The recombinant poxvirus of claim 2, wherein the immunogenic bacterial carrier protein further comprises a single insertion or double insertions atone or more selected positions therein, wherein the one or more selected positions are amino acid positions 32, 33, 74, 101, 122, 166, 185, 240, 253, and 317 in the immunogenic bacterial carrier protein.
13. A composition comprising the recombinant poxvirus of any one of claims 1 to 13 and a veterinarily acceptable canier formulated for oral or intramuscular administration.
14. A method of inducing immunocontraception in an animal subject, comprising administering to the subject an effective amount of a recombinant poxvirus comprising a heterologous nucleic acid sequence encoding at least one immunocontraceptive antigen, wherein the antigen comprises a Gonadotropin-Releasing Hormone (GnRH) peptide bound to an immunogenic bacterial carrier protein.
15. The method of claim 14, wherein the administration is performed via a single dose delivered by oral ingestion of a baited canier or by intramuscular injection.
16. The method of claim 14, wherein the animal subject is selected from the group consisting of swine, canids, felids, and rodents.
17. The method of claim 14, wherein the administration induces the production of anti-GnRH antibodies that neutralize native GnRH and suppress the secretion of Follicle-Stimulating Hormone (FSH) and Luteinizing Hormone (LH).
18. The method of claim 14, wherein the administration results in at least a 70% reduction in testis weight relative to a mock-vaccinated control within 8 weeks.
19. The method of claim 14, wherein the administration results in 100% suppression of serum testosterone levels.
20. The method of claims 1 or 10, wherein the Gonadotropin-Releasing Hormone (GnRH) peptide bound to an immunogenic bacterial carrier protein is a chimeric protein or a fusion protein.
21. A method of controlling a population of feral or invasive animals, comprising administering the composition of claim 14 to a subset of individuals in the population, wherein the recombinant poxvirus is capable of animal-to-animal transmission.
22. An isolated single-domain antibody (VHH nanobody) that selectively binds gonadotropin-releasing hormone (GnRH) or follicle-stimulating hormone beta subunit (FSH 0), wherein the VHH nanobody comprises an amino acid sequence selected from the group consisting of SEQ I D NOs: 13-40, or an amino acid sequence having at least 90% sequence identity to any one of SEQ ID NOs: 13-40 and retaining said selective binding to GnRH or FSH.
